The Role of Extracellular Histones in Complement Activation and Phagocytosis by Qaddoori, YB
  
 
The Role of Extracellular Histones 
in Complement Activation and 
Phagocytosis 
 
 
 
Thesis submitted in accordance with the requirements of the 
University of Liverpool for the degree of Doctor in Philosophy 
 
By 
Yasir Qaddoori 
July, 2018  
 
 
1 
 
Abstract 
 
Complement activation leads to membrane-attack complex (MAC) 
formation which can lyse not only pathogens but also host cells. 
Histones can be released from the lysed or damaged cells and serve as 
a major type of damage-associate molecular pattern (DAMP), but their 
effects on the complement system are not clear. 
 In this study, we pulled down two major proteins from human serum 
using histone-conjugated beads, one was C-reactive protein and the 
other was complement component C4 as identified by mass 
spectrometry.  In Surface Plasmon Resonance (SPR) analysis, histone 
H3 and H4 showed stronger binding to C4 than other histones with 
KD around 1.0 nM. The interaction did not affect C4 cleavage to C4a 
and C4b. Since histones bind to C4b, a component of C3 and C5 
convertases, their activities were significantly inhibited in the 
presence of histones. Although it is not clear whether the inhibition 
was achieved through blocking C3 and C5 convertase assembly or just 
through reducing their activity, the outcome was that both classical 
and mannan-binding lectin (MBL) pathways were dramatically 
inhibited.  Using a high concentration of C4 protein, histone-
suppressed complement activity could not be fully restored, indicating 
C4 is not the only target of histones in those pathways.  In contrast, 
the alternative pathway was almost spared but the overall complement 
activity activated by zymosan was inhibited by histones. Therefore, 
we believe that histones inhibiting complement activation is a natural 
feedback mechanism to prevent the excessive injury of host cells.   
In addition, the effect of extracellular histones on phagocytosis has 
been investigated. Surprisingly, histone-induced inhibition of 
complement activation did not reduce phagocytosis because histones 
themselves are able to enhance phagocytosis. The underlying 
molecular mechanism is not clear. Blocking toll-like receptors 2 and 4 
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only partially reduced the phagocytic activity. Further study is 
required. 
In summary, histone release not only damages cells contacted but also 
initiates protective mechanisms, including limiting excess 
complement activation and facilitating bacterial clearance through 
phagocytosis.  
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Chapter 1: General Introduction 
1.1 Danger signals: DAMPs & PAMPs 
In recent decades, the danger model of the immune system has been 
predicted, it was proposed that the host immunity prioritises to 
damage rather than foreignness in the sense of the immune response 
(1). Moreover, this approach assumed that the body’s immunological 
recognition is not confined to differentiation between self and non-self 
but extends to safe-unsafe structure discrimination (2).  
Thus, the danger model has been widely expanded to incorporate 
numerous patterns that can elicit the immune response which can be 
pathogen related or result from tissue injury, necrosis or cells that 
undergo non-programmed death (1). 
The inflammation cascade is stimulated by either pathogen-associated 
molecular patterns (PAMPs) or damage-associated molecular patterns 
(DAMPs). Intriguingly, similar inflammatory responses can be 
triggered by these two types  (3). 
DAMPs are endogenous components that mostly exist inside cells and 
are secreted as a result of cell injury, activation or irregular death; they 
comprise various types of molecules such as those that can modulate 
coagulation like histones, high mobility group box 1 (HMGB1), 
polyphosphates, DNA, RNA and small molecules such as ATP (4). 
Moreover, some DAMPs can be part of the extracellular or degraded 
matrix like hyaluronan (5),  numerous leaderless secretory proteins 
LSPs can be released by dying cells such as HMGB1 which is able to 
elicit inflammation and act as a DAMP when secreted, in addition to 
its role as a nuclear factor (6). 
Following cell injury, DAMPs and some intracellular substances like 
oxido-reductases and non-protein thiols can be released, this modifies 
the extracellular redox state in a way that simulates the reducing 
intracellular environment (7). Such extracellular redox alteration 
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protects translocated DAMPs from being inactivated by oxidation and 
enhances their pathological potency (7).  
Sepsis is a life-threatening organ dysfunction due to a disordered host 
response to infection which may be remarkably augmented through 
endogenous constituents (8), like extracellular RNA, DNA, and 
histones (9). Thus it is one of the outstanding clinical manifestations 
that shows the synergistic role of DAMPs and PAMPs in a host 
immune response, where endogenous alarmins or DAMPs are released 
passively after cell death such as histones, or actively like 
HMGB1(10), whereupon these DAMPs are recognised by the innate 
immune system receptors, leading to an early activation of different 
serine proteases systems such as coagulation and complement cascade 
(11). Together with the pathogenic immune response, this results in a 
systemic immune response (10). Recently, it was postulated that 
sepsis is characterized with both pro- and anti-inflammatory early 
activation (12), alongside significant modifications in non-
immunologic pathways such as cardiovascular, neuronal, autonomic, 
hormonal, bio-energetic, metabolic, and coagulation (8), (Fig. 1.1). 
During infections and through their molecular patterns, 
microorganisms are recognized by Toll-like receptors (TLRs), NOD-
like receptors (NLRs) and RIG-I- like receptors (RLRs), thus 
commences a host response which thereafter develops to inflammation 
(13-15). When this infection is accompanied by tissue injury and 
release of DAMPs from damaged or dying cells, an inflammatory 
reinforcement can occur, which due to DAMP interaction with pattern 
recognition receptors (PRRs) up-regulates the inflammatory events 
(7). Unlike the infectious events, even in the absence of pathogen, 
stressed and damaged cells can still initiate an inflammatory response 
and recruit the related cells after DAMP liberation (7).  
Some non-infectious inflammatory responses can lead to extensive 
cell death, these include early phase of acute pancreatitis, 
acetaminophen-induced liver injury, ischaemia-reperfusion-induced 
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brain injury, myocardial infarction and blunt trauma, where high 
levels of cytokines and chemokines (16, 17)  in addition to 
intracellular contents release events occur (18-20). 
DAMPs and PAMPs use several overlapping receptors such as TLR4, 
TLR3, TLR7-9 and both NLRs and RLRs (21), on this basis of 
receptor similarity, it would not be surprising to find a similarity 
between infectious and sterile inflammatory responses. 
 
 
Figure 1.1 The host response in sepsis. Pro-inflammatory responses 
and anti-inflammatory immune suppressive responses both 
occur in sepsis. Inflammatory responses are elicited via 
interaction between PAMPs or DAMPs and pattern 
recognition receptors (PRRs). Excessive inflammation with 
subsequent tissue damage and necrotic cell death lead to 
release of DAMPs that can sustain ongoing inflammation. 
The pro-inflammatory response is promoted by activation of 
leukocytes, complement, and the coagulation system. The 
anti-inflammatory immune suppressive response relies on 
impaired function of immune cells, neuroendocrine 
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regulation, and suppression of pro-inflammatory gene 
transcription. Substantially, direction, extent, and duration of 
the septic response are determined by both host and pathogen 
factors. Adapted from Wiersinga et al (22). 
 
1.2 Histones 
Histones were first found in goose erythrocytes by Albrecht Kossel in 
1884 (23).  Normally, they are highly alkaline intra-nuclear proteins 
that are present in eukaryotic cells. However, recent studies found 
some histones are homologous in certain Archaea (20). The basic task 
of these nuclear proteins is to pack and sort the DNA into functional 
units (Nucleosomes) as well as gene regulation (24). 
Histones are also liberated through neutrophil extracellular traps 
(NETs), these traps have a significant protection role against 
exogenous pathogens (25, 26). Basically, histones are divided into two 
functional groups which are core histones that includes H2A, H2B, H3 
and H4, while the other group is linker histones which includes H1 
and H5 (H1 variant in Avian erythrocytes (20). The four core histones 
possess analogous structural characteristics, composed of a central 
helix flanked by two helix-strand-helix motifs (27).  Core histones 
form a “nucleosome” when two turns of 147 base-paired DNA strand 
wraps around an octamer of core histones complex (28) (Fig. 1.2). 
It has been found that whilst H3-H4 heterodimers further arrange to 
form a tetramer structure that is essential for commencing nucleosome 
construction, H2A-H2B homodimers do not submit to these structural 
changes and they are stable only in this dimeric form (20). 
Furthermore, core histones organize gene structure and expression 
through their N-terminals tails’ post transitional modifications PTMs 
(29), these modifications include acetylation, methylation, 
phosphorylation, ubiquitination, citrullination, sumoylation, 
biotinylation or ADP ribosylation (20, 30). On the other hand, linker 
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histones attach two neighbouring nucleosomes together and control 
DNA accessibility to other intra-nuclear proteins, and so regulate the 
epigenetic modifications of transcription as well as the replication and 
repair processes of DNA (31).  In the case of histone scarcity, 
genomic DNA would be in a disordered and non-functional form (32). 
Yet, Singh et al has found that excessive histone production in 
budding yeast has a cytotoxic effect which reflects the importance of 
many mechanisms that regulate their synthesis inside cells (33).  
 
 
 
Figure 1.2 Structure of histones and nucleosome assembly. A 
nucleosome has octameric histone molecules. An octamer is 
composed of two H2A-H2B homodimer and one (H3-H4) 
tetramer, adapted from Silk et al (31). 
 
 
1.2.1 Extracellular histones, translocation and pathology 
In the face of their role in nucleosome construction and chromatin 
stability, misplaced histones in the extracellular space can display 
toxic and pro-inflammatory properties both in vitro and in vivo (34), 
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this happens when they are released passively or actively by dead or 
triggered cells (20, 35). Furthermore, extracellular histones represent a 
cell death alarm that stimulates the immunological response as well as 
the body repair program (36). 
These outcomes qualify extracellular histones to be one of the novel 
damage associate molecular patterns (20). Thus, extensive research is 
ongoing to interpret their distressing role in various pathological 
circumstances, where my research group was one of the outstanding 
examples in this field (35, 37-39). 
Mainly, histones are released extracellularly in response to various 
stress conditions such as infection, trauma and tissue injury (40), 
hence they are secreted to extracellular spaces through different routes 
including extracellular traps of active immune cells, cellular apoptosis 
and necrosis (20).  
During sepsis, histones can be released into the blood stream and act 
as DAMPs due to cell death and prolonged inflammation (37). 
Hereby, it has been found that they are toxic both in vitro and in vivo 
and play a role in sepsis-induced endothelial dysfunction, organ 
failure and death (34). The cytotoxic effect was assigned mainly to H3 
and H4 translocation which binds to cellular membranes, 
accompanied by elevated calcium influx in endothelial cells in vitro 
(34).  In vivo experiment showed that intravenous histone 
administration to mice caused neutrophil accumulation within the 
microcirculation, serious endothelial injury, dysfunction and 
coagulation which resulted in animal death (34) . 
Peritonitis is an inflammation of the peritoneum which is also initiated 
by a microbial origin such as bacteria or fungi (20). Histone release 
from necrotized cells during peritonitis can stimulate sterile 
inflammation in an NLRP3 ASC-caspase1 inflammasome dependent 
mechanism, mice administration with H4 abs and activated protein C 
(APC) restricted the histone dependent peritonitis significantly (41). 
Another peritonitis model showed histone-induced distant organ 
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injury to the heart, which led to mechanical and electrophysiological 
dysfunction that was reduced by anti-histone antibody treatment (37).  
Activated neutrophils can be another source of histones, as they 
expelled in the form of NETs, to ensnare bacteria in sepsis (42). NETs 
are large extracellular web-like structures which are stuffed with 
abundance of nuclear and intracellular components such as DNA, core 
histones and anti-microbial proteins (e.g. myeloperoxidase and 
elastase), that are discharged out of the neutrophils through a process 
termed “NETosis” (20, 42-44), these traps can bind and kill pathogens 
extracellularly and independently (10). However, dysregulation and 
excessive NETosis have deleterious consequences to the host and can 
cause adjacent cell death (27, 43).  
 Furthermore, non-conserved forms of histones within NETs can result 
in cell damage and vascular thrombosis (40). Although DNase 
administration can decompose NETs and eliminate DNA in vivo, it 
does not decrease the tissue injury to a significant extent as it does not 
affect histones (45), hereby it clarifies the cytotoxic side of 
extracellular histones (40). Histones released through NETosis can 
also mediate inflammation in several autoimmunity associated 
diseases, e.g. rheumatoid arthritis (46) and systemic lupus (47). 
Extracellular histone autoantigens can also bind with DNA and form 
histone-DNA complex and prohibit DNA degradation (20, 46). 
Another source of extracellular histone release can be extensive cell 
death associated with non-infectious conditions, such as blunt trauma 
(35), ischaemia-reperfusion-induced brain injury (48), myocardial 
infarction (49), liver injury (50) and acute pancreatitis (39). In these 
cases, a heightened release of cellular content surpasses the 
neutralizing capacity (51) in addition to the secretion of many 
inflammatory mediators (31). 
Trauma is usually associated with extensive tissue necrosis and 
cellular death, which elicits a systemic inflammatory response 
syndrome that clinically resembles sepsis.  It has been found that 
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histones were cytotoxic when trauma patients’ serum that 
contains >50µg/ml of histones were incubated with endothelial cells 
(35). Furthermore, circulating histone concentrations have been shown 
to be significantly raised in patient serum after severe non-thoracic 
blunt trauma (35). Likewise Johansson et al showed that extracellular 
histones tend to be associated with anti-coagulant activity in traumatic 
injury patients (52). Taken together, these observations highlight the 
pathological role that circulating histones may play in trauma.  
In the same context, extracellular histone levels were found to be 
significantly raised in animal models with other sterile inflammatory 
conditions such as liver (53), kidney (54), lung (55) and brain injury 
(48), revealing their role in such types of inflammation.  Moreover, 
these histone DAMPs mediate tissue injury through cytotoxic and pro-
inflammatory mechanisms, as they bind to TLRs in the presence of 
myeloid differentiation factor 88 (MyD88), to release pro-
inflammatory cytokines such as tumour necrosis factor alpha (TNF-α) 
and interleukin 6 (IL-6), to produce a robust inflammation (20).  
Another non-infectious inflammatory disorder that may lead to cell 
death is acute pancreatitis (20), in which severe complications of 
necrosis and/or multiple organ failure (MOF) can occur in critical 
cases (56). Histones can be released from necrotized cells and elicit a 
sterile inflammation (35). In the same vein, Xelong et al clarified that 
circulating histone levels rise significantly in a mouse pancreatitis 
model and correlate with disease severity and distant organ failure 
(57). Furthermore, a recent study has revealed that measuring 
circulating histones in pancreatitis patients with abdominal pain can 
predict future organ failure and mortality (39). 
Extracellular histones play a role in ocular disease pathology like 
retinal detachment (RD); Kwano et al has demonstrated that histone 
concentration was increased in RD patients (24). In a rat RD model, 
histones have pro-inflammatory and cytotoxic effects at 
concentrations of >10 and >20µg/ml respectively (24); histone 
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modification also associates with some ocular diseases e.g. retinal 
degeneration, neovascular response, retinitis pigmentosa and 
spinocerebellar ataxia type (58). On the other hand, it has been found 
that extracellular histones as well as their epigenetic modification 
participate in some central nervous system illness like Huntington’s 
disease (59, 60), (Fig.1.3). 
 
 
Figure 1.3 Histone related tissue injury, Chen et al (20). 
 
1.2.2 Extracellular histone toxicity mechanisms  
Histones can cause a multiple organ dysfunction (MOD) through their 
tripartite synergetic effects including inflammatory, pro-coagulant and 
cytotoxic effects (38). 
 
1.2.2.1 Pro-inflammatory influence of extracellular histones 
Several TLRs have been found to be associated with recognition of 
both DAMPs and PAMPs and the subsequent immune response (21), 
so this makes the infectious and non-infectious  inflammatory  
response share many characteristics (3). 
The activation of TLR2/TLR4 by histones leads to release of many 
pro-inflammatory cytokines e.g. IL-6, IL-10 and TNF-α through 
MyD88 associated mechanism as well as platelet activation (6, 61-64), 
which in turn controls the provoked immune response in non-
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infectious  acute organ injury (AOI) (31). Moreover, knocking out 
TLR2 and TLR4 genes in mice models was found to be protective 
against lethal histone dosages (53, 62) and TLR2 and TLR4 
monoclonal abs blocked the corresponding receptors and protected 
wild type animals (31).  Nevertheless, TLR9 may also participate in 
the non-infectious inflammatory response during hepatic IR injury of 
animal models (65), in which exogenous histones activate TLR9 and 
result in cytokine release then massive tissue necrosis, whereas TLR9 
null mice have no response to histones (66).  Additionally, TLR9 
stimulation may play another role in the sterile inflammation cascade 
through NLRP3 inflammasome-caspase1 activation (67), leading to 
cytokine secretion and leucocyte recruitment (68). Histone binding to 
TLR9 activates these receptors, thus it triggers mitochondrial reactive 
oxygen species (ROS) generation, which in turn prompts the NLRP3 
inflammatory pathway of pro-inflammatory Kupffer cells (KCs) 
during liver injury after hepatic ischaemia/reperfusion (67). 
1.2.2.2 Extracellular histones and impact on coagulopathy 
Conventionally, coagulation is an organised process through which 
platelets and coagulation proteins synergise to form a blood clot and 
so culminates in haemostasis; disorders in such mechanism may lead 
to haemorrhage or thrombosis (69). There is an association between 
thrombosis and inflammation, they share a variety of mechanisms in 
this pattern of crosstalk (70), whereby pro-inflammatory histones can 
have a role when they are released extracellularly in some 
pathological conditions  (6). Abrams et al (35) has found that 
thrombin–anti-thrombin complexes (TAT) were significantly 
increased in the circulation of trauma patients’ and correlate 
significantly with histone concentrations. In vivo, exogenous histones 
have been shown to demonstrate vacuolated endothelium, intra–
alveolar haemorrhage and macro and microvascular thrombosis, 
which culminate in organ failure in mice models (34). Among all 
histone types, H4 was the most potent in inducing platelet aggregation 
and platelet-dependent thrombin generation in mice in vivo and in 
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vitro (16).  Sameraro et al showed that extracellular histones activate 
platelets through their TLR2/TLR4 receptors which leads to enhanced 
platelet-mediated thrombin generation in humans (61). TLR2 and 
TLR4 induce platelet activation through several signalling pathways 
(e.g., ERK, Akt, p38, and NF-κB), induction of calcium influx and 
fibrinogen recruitment (16). By interacting with TLR2 and TLR4, 
histones stimulate tissue factor expression (TF) in human endothelial 
cells as a result of NF-κB and AP-1 transcription factor up-regulation 
(6). 
However, histones may adopt other mechanisms to promote 
thromboembolism such as suppressing thrombomodulin (TM)-
dependent protein C activation where H3 and H4 were the most active 
effectors (71) . This effect could be neutralized with recombinant TM 
which binds to histones and protects mice against Histone H3-induced 
lethal thrombosis (72). Circulating histones play a role in the crosstalk 
between coagulation, inflammation and innate immunity (Fig. 1.4) 
which qualifies them to be interesting therapeutic targets in 
haematological disorders and critical illness (40). Another study 
demonstrated that H4 can bind to prothrombin and generate thrombin 
independently of the coagulation cascade via auto-activation (73). 
Histones cause endothelial damage via Willebrand factor–mediated 
leucocyte recruitment, platelet activation, inhibition of the protein C 
anticoagulant pathway, and prothrombin auto-activation thus 
enhancing the microvascular thrombosis (34, 38, 62, 73). 
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Figure 1.4 Histones are the cornerstone of interaction between 
coagulation, innate immunity and inflammatory 
pathways, adapted from Alhamdi et al (40). 
 
1.2.2.3 Nonspecific TLR independent cytotoxicity of free histones 
Extracellular histones may have direct cytotoxic effects to epithelial 
and endothelial tissue, herewith administrating exogenous histones 
results in significant reduction in cell viability (31). A high binding 
avidity was first found between histones and anionic phospholipids 
(Cardiolipin and phosphatidylserine) in 1994 (1). In the same vein, 
recent researches have suggested that extracellular histones bind to 
phospholipid–phosphodiester bonds, in the same manner as they bind 
to DNA, which causes increase of transmembrane conductance, cell 
swelling, calcium ion influx and cytolysis (34, 35, 74). Consequently, 
intracellular components will be discharged, culminating in cell death 
due to cellular functions deteriorating (31). 
Abrams et al has found that this histone-membranous phospholipids 
binding and the consequent calcium influx associates with vascular 
endothelial permeability increase, myeloperoxidase and cytokine 
release, coagulation activation and NETosis (35). Blocking TLR2/4 
receptors did not alter the endothelial cell calcium influx, while 
controlling the extracellular Ca
+2
 or treating with histone abs has 
cytoprotective effects. (35). 
Interestingly, the inflammatory mediator C-reactive protein has been 
found to compete with histones in opposition to their phospholipids 
binding (75), thus this interaction protects against histone-
phospholipid mediated cytotoxicity by disrupting histones binding to 
phospholipids, preventing histone association with cellular 
membranes and so blocking the calcium influx cytotoxicity 
mechanism of histones (75). 
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Besides, intracellular excess of Ca
+2
 ions possibly correlates with 
cardiac injury which results from cardiomyocyte injury and death (38, 
76, 77). In human MCF7 cancer cells, Ganapathy et al has revealed 
that H1 promotes extracellular Ca
+2
 influx and intracellular release, 
taking into account the cytotoxic impact due to the higher levels 
mainly from the extracellular influx (78). Histone mediated-calcium 
influx events have been observed in other tissues like platelets (63), 
urinary bladder epithelium (79) and thymocytes (80). 
Altogether, histone-enhanced inflammation, coagulation, and 
cytotoxicity effects may synergistically result in multiple organ 
dysfunctions that are common in critical illness (38). 
 
1.2.3 Extracellular histones and sterile acute organ injury 
 1.2.3.1 Lung 
Acute lung injury (ALI) has a  high mortality rate which is around 
40% (81) and is mostly attributed to other primary factors like trauma 
or ischemia (31).ALI causes alveolar and lung endothelial cell 
functional alteration, which in turn leads to improper pulmonary 
circulation, protein permeability increase, cell death and inflammatory 
response that culminates in permanent lung dysfunction, MOF and 
late mortality (23, 25, 31, 35).  
In mouse models mortality is observed within 4hours after histone 
infusion (75mg/kg), as histone treatment led to cyanosis and dyspnoea 
which indicates both lung and cardiac failure (35). Furthermore, 
histological microscopy has shown clear alteration in lung tissue such 
as oedema, neutrophil-obstructed alveolar capillaries and pulmonary 
haemorrhage, while liver and kidney displayed mild pathological 
alteration like vacuole formation (35). On the other hand, anti-histone 
abs (ahscFv) co-infusion diminished histone-mediated lung injury 
significantly (35).  
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In humans, severe blunt trauma patients showed significant rapid 
increase of circulating histone levels, which passed the toxicity 
threshold and correlated with ALI severity, endothelial damage and 
coagulation (35). Serum histones over 50µg/ml were also toxic to 
cultured endothelial tissue (35). In the same study, it was concluded 
that histones may exhibit their cytotoxicity effects through calcium 
influx and coagulation mechanisms in acute lung injury (35).With 
regard to the mechanism of histone release, an ALI mouse model 
clarified that complement receptors C5aR and C5L2 are contributors 
in such a process (55).  
Animal models of transfusion-associated lung injury (TRALI) 
displayed an obvious NET-mediated inflammation (82), where platelet 
activation stimulates NETosis from neutrophils leading to oedema and 
vascular endothelial permeability in lung tissues (27), which could be 
reduced with anti-histones abs (82).  
Altogether, these data indicate that lungs are the most susceptible 
organs to circulating histone toxicity, this may due to the dense nature 
of the capillary network in the pulmonary microcirculation (35). 
1.2.3.2 Heart 
Generally, ischemia/reperfusion (I/R) is the main cause for cardiac 
injury in which shortage of the oxygen supply to cardiomyocytes led 
to necrosis and discharge of immunogenic intracellular constituents 
and a cascade of inflammation and repair (31, 49). 
Soon after myocardial infarction (MI), uncontrolled histone release 
from necrotized cells occurs, and then histones aggregate within the 
myocardium and promote dose dependent cytotoxicity to cardiac 
myocytes (49). Furthermore, treating the mouse model with DNase 
protected myocardiocytes from histone-mediated cell death and left 
ventricular dysfunction after IR. It was supposed that DNAse 
disseminated extracellular chromatin by linker DNA degradation 
which reduced local histone concentrations and thus cytotoxicity (49). 
 
 
30 
 
On the other hand, Savchenko et al has demonstrated that NETs are 
also incorporated in the inflammatory cascade and exacerbate cardiac 
ischemia injury in a mouse model (83). Peptidylarginine deiminase 4 
(PAD4) is essential enzyme for histone citrullination, which is a 
posttranslational histone process for decondensation of chromatin 
during NETosis, Martinod et al has shown that venous thrombosis can 
result from NET formation via PAD4 (84).  
It should also be mentioned that PAD4 knock-out mice showed no 
NETs formation (85), lack of PAD4 decreased leucocyte infiltration 
and NETosis, hereby having a cardio-protective impact in a mouse 
model of acute myocardial infarction (AMI) (83). 
1.2.3.3 Liver 
Non-viral hepatitis can result from liver ischemia and drug toxicity, 
this type of sterile inflammation may lead to hepatic enzyme and 
synthetic function disorder (86, 87). This dysregulation brings out 
cardiovascular instability, cerebral edema, coagulopathy, renal failure, 
metabolic disturbance, hemodynamic instability, and susceptibility to 
infection which are the main clinical characteristics of acute liver 
failure (ALF) (31, 59, 86). 
Histone release after hepatic sterile inflammation can activate 
TLR2/TRL4/TLR9 on KCs, amplify the inflammation and cause a 
robust release of a number of cytokines (53, 62, 65, 66). Whilst H1/H4 
have proved to play a major role in alveolar cell death in ALI (82), H3 
which displayed inert properties in ALI (27, 55)  has shown to have 
significant effects on hepatic damage that can be reduced with anti-H3 
abs which minimized the mortality, and serum TNF-α and IL-6 in 
ALF animal models (66).  
In humans, ALF patients’ sera had significantly increased histone 
level which can trigger hepatocyte death and up-regulate U937 
(Monocytes) cytokine release activity (50). Using histone neutralizing 
agents like non-anticoagulant heparin prevented the histones’ pro-
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inflammatory effect, which demonstrates that circulating histones are 
vital mediators of ALF patients’ systemic inflammation and cell death 
(50). 
 Furthermore, levels of the endothelial tissue dysfunction marker 
Angiopoietin-2 increased notably in ALF patients, which may be a 
response to the cytotoxic impact of extracellular histones (59).   
NETs also contribute to hepatocytotoxicity (31, 44). NETosis is 
initiated upon activation of  neutrophil receptors TL4 and TLR9-
MyD88 by injured hepatocyte histones, which stimulate KCs to 
release pro-inflammatory mediators (31). This process could be 
suppressed in mice by treatment with NETosis inhibitors e.g. peptidyl-
arginine-deiminase 4 PAD4i or DNAse1, which in turn has led to the 
suppression of NET formation as well as reduction in HMGB1 and 
histone mediated hepatic injury (31, 44).  
In addition, it has been recently shown that there is an association 
between acute pancreatitis and liver inflammation, with the liver being 
implicated as a main source of DAMPs histones in animal models of 
pancreatitis-associated liver injury (88). 
  1.2.3.4 Kidney 
Acute ischemic or any toxic insult can lead to acute renal failure, 
which is characterized by a sudden reduction in glomerular filtration 
function and consequently results in azotemia (89). Acute ischemic 
kidney injury associates with high rate of morbidity and mortality 
(90). Frequent insult to the renal parenchyma may cause enduring 
necrosis and renal failure, which can develop to a chronic kidney 
disease if untreated (91). Cell death that attributes to apoptosis and 
necrosis is a main manifestation of ischemic renal failure which is 
prolonged via cytokine release and neutrophil invasion (92).  
Histones are released extracellularly from necrotic tubular epithelial 
cells in acute renal ischemia (54, 93). Those free histones exhibit a 
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dose-dependent cytotoxic effect for both renal endothelium and 
tubular epithelium (93). 
Furthermore, extracellular histones aggravate leukocyte adhesion and 
enhance the vascular permeability of the renal arteries (93). However, 
histones-mediated pro-inflammatory effects could be reduced by 
blocking with H4 monoclonal abs (31, 93).  
TLR2/TLR4 receptors have been shown to mediate the inflammatory 
cascade in acute kidney injury via stimulating MyD88-NFkB and the 
mitogen-activated protein kinase (MAPK) signaling mechanisms,   
while null-MyD88 and TLR mice have shown alleviated pro-
inflammatory manifestations (31, 64, 94).  
 
1.3 Relief of adverse effects of histones: Therapeutic approaches  
As histones are considered potential mediators in the interaction 
between different host systems including inflammation, coagulation 
and innate immunity (40), so they represent a useful therapeutic target 
in histone-associated clinical conditions (40). From this direction 
comes the importance of finding therapeutic strategies to reduce the 
harmful effects of extracellular histones, which may be based on three 
main elements including blocking histone release, extracellular 
histone neutralisation and blocking of histone-induced signalling (31). 
1.3.1 Histone release blocking 
Targeting NETosis had a successful impact in animal models of AOI 
and sepsis (31).Various PAD inhibitors can decrease the pathological 
manifestation of many diseases models e.g. collagen-induced arthritis, 
colitis, atherosclerosis, lupus, kidney injury, hypoxic ischemia and 
cancer (95). Specifically screened PAD4 suppressors GSK199 and 
GSK484 were able to reduce histone citrullination and diminish NET 
formation (96), which had greater protective effects than DNase 
treatment, against tissue damage (45). In addition, Kusunoki et al (97) 
has clarified that the pan-PAD inhibitor C1-amedine was able to 
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suppress NETosis both in vitro with human neutrophils and in vivo in 
a mouse model. However, DNase through breaking down 
nucleosomes is still able to alleviate NETs and extruded intracellular 
histones toxicity, due to extracellular chromatin dispersion by linker 
DNA degradation, that reduced local histone concentrations and 
significantly ameliorated MI associated left ventricular remodelling in 
mice (31, 49). Moreover, a recent study showed that treating mice 
with PAD4 inhibitor (YW3-56, YW4-03) or DNase1, suppressed NET 
generation and decreased HMGB1 and histone-mediated liver I/R 
injury (44). Another inhibitor for NETosis was found to be APC (98), 
where a recent study has revealed that APC can bind to human 
leukocytes and prevent phorbol 12-myristate 13-acetate (PMA) or 
activated platelets from stimulating NETosis, APC at theraputic 
concentrations may result in NETosis inhibition via EPCR-, PAR3-, 
and Mac-1-dependent pathways (98). Developing APC mutants with 
cytoprotective and anti-inflammatory but not anticoagulant activity is 
interesting for therapeutic use in certain inflammatory diseases, 
without compromising the haemostasis (98-100). 
 1.3.2 Released histones neutralisation 
The acute phase protein CRP associates with both innate and adaptive 
immunity, it participates in infections, non-infectious, autoimmune 
and apoptotic scenarios (75, 101-104). Histone-CRP complexes have 
been demonstrated in ICU patients’ serum with high levels of both 
CRP and histones (75). When this serum is incubated with endothelial 
cells, CRP has shown a cytoprotective effect due to preventing 
histones from integrating into plasma membranes and causing the 
consequent calcium influx; this protective role is due to competition 
for binding with histones to membranous phospholipids (75, 101). In a 
mouse model treated with exogenous histones, it has been 
demonstrated that infused CRP neutralised the cytotoxic effects of 
histones via decreasing vascular permeability, suppressing histone-
mediated-coagulation and endothelial damage (75). Histological 
examination showed that CRP infusion prolonged mouse viability in a 
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dose dependent manner, due to significantly reduced lung oedema, 
haemorrhage and thrombosis in mice challenged by a lethal dose of 
histones (75). 
Disseminated intravascular coagulation (DIC) is associated with 
increased levels of circulating histones (40, 72). Recombinant 
thrombomodulin (rTM) treatment for DIC patients has been validated 
in Japan (20); it was demonstrated that rTM binds directly to histones 
and rescues mice from lethal thrombosis; this protective impact is 
organised via APC-dependent and independent pathway (71, 72, 105). 
APC have been shown to cleave histones both in vitro and in vivo; 
such cleavage yields fragments that are unable to cause endothelial 
cell damage and dampen the cytotoxicity (106). However, developing 
APC mutants with cytoprotective and anti-inflammatory but not 
anticoagulant activity should be the targeted approach, since 
administration with conventional APC may cause serious 
complications to homeostasis (98). 
Heparin has been found to neutralize histone toxicity and histone-
mediated platelet activation both in vitro and in vivo (20).  In the same 
vein, Wildhagen et al (74) demonstrated that non-anticoagulant 
heparin binds to histones and inhibits their toxic effects in vitro; the 
same study also clarified that heparin decreased the mortality in 
mouse models of septic and sterile inflammation. In another study 
(63), heparin was also able to prevent extracellular histone toxicity in 
vitro and upon infusion into mice, since it prohibits histones from 
platelet activation and prevents histone-induced thrombocytopenia, 
tissue damage, and animal death (63). Intriguingly, treatment with 
non-anticoagulant heparin excludes the risk of haemorrhage and 
makes it a promising strategy for treating septic patients (74).  
Substantially, anti-histones abs have demonstrated protective effects 
when used in many AOI animal models (27, 34, 35, 53-55, 62, 66, 67, 
82), which is reflected by inflammation amelioration, functional score 
and overall survival (31). 
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Anti-histone antibody protected mice against transfusion-related acute 
lung injury (82) and also attenuated acute lung injury in a murine 
model of trauma and in a histone-infusion mouse model, as well as 
protecting the mice from histone-associated lethality (35). Moreover, 
antibodies to histones neutralized the immunostimulatory effects of 
histones, inhibited intra-renal inflammation, neutrophil infiltration and 
ameliorate the kidney function (54), and reduced neutrophil 
recruitment by necrotic cells in vitro and in vivo (107). In addition, 
histones-mediated cardiotoxicity as well as cardiac dysfunction has 
been abrogated using anti-histones abs (38). 
1.3.2.1 Others 
Lam et al (108) indicated that albumin can bind to H4 and prevent 
H4-mediated platelet aggregation; the study attributed this binding 
affinity to charge variance between the histone and albumin, since 
neutralized albumin exposed both less H4 affinity as well as reduced 
inhibitory effect. Yet, the study’s findings have not been further 
confirmed, and lack in vivo experiments and were applied in a serum 
or plasma-histone only environment, which did not include any other 
cell signalling and incorporation. Furthermore, the concentration of 
H4 was substantially below the toxic value (10µg/ml) which should be 
tackled by the immune system, taking into consideration that platelet 
activation is one of many mechanisms that histones adopts to up-
regulate the host response.    
A shotgun proteomics study has pointed out that exogenous histones 
precipitate numerous plasma proteins like lipoproteins, proteinase 
inhibitors, complement proteins, coagulation factors and 
immunoglobulins, suggesting a possible protective effect of histone-
protein insoluble copolymer formation (109). However, the study has 
stated that the exact pattern of interaction between alike individual 
histones and plasma proteins was beyond its scope (109).  
Regarding complement subunits that aggregate with histones, this 
study has also stated that comprehensive work would be important to 
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assign whether this represents simple protein deposition, or whether it 
can be attributed to complement activation (109). In addition, the 
cytotoxicity of circulating histones has been well reviewed (20, 31) 
and established in a clinical context by our group (35, 37-40).  
1.3.3 Histone-TLR signalling blocking 
Extracellular histones have been shown to interact with many TLR 
receptors comprising TLR2, TLR4 as well as TLR9 (54, 61, 62, 66). 
Activating TLRs via binding with histones leads to stimulating 
different inflammatory, coagulopathy and histone-mediated cytotoxic 
effects in various clinical conditions (110).  
TLR4 null mice were protected against histone-related lethal effects 
upon exogenous histone infusion (62). In addition, Ekanet et al 
showed that blocking TLR4 reduced histone-associated toxicity to 
endothelial cells that were infused with a toxic concentration of 
histones (50µg/ml) (111). Blocking platelets’ TLR/TLR4 receptors 
with monoclonal abs resulted in suppression of both platelet activation 
as well as thrombin generation (61). Moreover, histones showed no 
effect in TLR9 inhibitor treated mice (66). Nevertheless, blocking 
TLR2/TLR4 has not revealed obvious protective impact according to 
Abrams et al (35). This seems logical if we take into consideration 
that histones have other mechanisms to cause deleterious toxicity 
effects, like calcium influx and up-regulating the coagulation cascade 
(38). 
Treatment with TLR blockers may ameliorate the clinical conditions 
in several cases despite not being the only distinctive mechanism that 
histones mediate to cause cell damage. However, as TLRs are 
important in innate immune defence after infection, so blocking this 
arm of the immune system may lead to significant immune system 
impairment (31). 
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 1.4 Novel innate immunity-histone release strategies 
The body’s defence strategy comprises three main chronological lines 
including anatomical and physiological barrier, innate, and adaptive 
immune response (Fig. 1.5). Innate immunity propagates the physical 
barrier protection and stimulates the later adaptive response (112).  
In general, the innate immune response involves cellular and humoral 
components which are interacting between each other to develop a 
protective inflammatory cascade. The cellular part includes 
haematopoietic cells like neutrophils, macrophages and natural killer 
cells (NKs) (113). While the humoral events are orchestrated by a 
distinct array of mediators, such as the contact system, naturally 
existing abs, complement, pentraxins (CRP) and microbicides 
peptides, which synergise to up-regulate the cellular events and 
provide the required protection (112, 114). Based on the similarity 
between PAMP and DAMP receptors (21) as well as the subsequent 
inflammation (3), a recent approach has included tackling of  DAMPs 
as one of the innate immune response functions (112).   
 
Figure1.5 Integral Human Immune System, Turvey et al  (112). 
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In addition to the initial overlapping between conventional PAMPs 
and DAMPs immune response, many studies have referred recently to 
the role of complement in the induction of NETosis (31). Bosman et 
al (55) showed that C5a receptors C5aR and C5L2 mediate NETosis 
and exacerbate the severity of ALI in a mouse model. Furthermore, 
another study has found that both TLRs and complement C3 are 
essential to stimulate NETosis, where no NET-related extracellular 
histones or even DNA have been found in TLR2/C3 null mice despite 
normal neutrophil recruitment (115). In a caecal ligation and puncture 
(CLP) animal study, Kalbitz et al and Grailer et al have stated that 
existence of histones in plasma was due to the interaction between 
three innate immune system arms, which are the complement system 
(C5a and its receptors), PMNs, and the NLRP3 inflammasome (116, 
117).  
In a review, Peter et al indicated that immune complexes stimulate 
NETosis via C5a receptors on neutrophils during ALI. Interestingly, 
neutrophil depletion in mice with C5a induced ALI decreased the H4 
levels dramatically in the bronchoalveolar lavage fluid (BALF) (55);  
silencing C5aR and C5L2 receptors in mice results in a sharp 
reduction in extracellular histone levels, which highlights that these 
free histones were released in a neutrophil-C5a dependent mechanism 
(55). Surprisingly, C3 null mice were still able to develop ALI and 
this ameliorated after anti-C5a treatment; the study has demonstrated 
that C5a generation was attributed to an unusual pathway via thrombin 
mediated C5-cleavage and only thrombin blockading terminated the 
C5a-PMNs associated ALI pathology in C3-/- mice (118).   
These outcomes revealed that extracellular histone release is also 
linked to a novel approach that incorporates complement components 
and innate immunity (Fig. 1.6), which raises a question about any 
other probable interaction that histones may have with complement 
proteins whether directly or indirectly. 
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Figure 1.6 Early initiating events in sepsis are complement 
activation with C5a/receptor incorporation which leads to 
death, Kalbitz et al (116).  
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1.5. The complement System 
1.5.1 Overview 
  The complement system represents one of the main arms of innate 
immunity that bridges innate and acquired immune responses (119), it 
supplies the body with a pivotal guard against pathogenic invasion 
(120), as well as a crucial participation in the pathogenesis of many 
autoimmune and inflammatory diseases (121) and a novel non-
inflammatory role in tissue regeneration and repair (122, 123). 
Initially, complement was considered as a heat-labile source in serum 
which “complements” antibodies in bactericidal function (124, 125). 
In terms of number of components, the complement system is 
composed of over than 50 proteins in plasma and on the surfaces of 
cells (126), these proteins comprise more than 3g/l, where they 
amount to around 15% of the globulins (124, 125, 127). 
Basically, the complement system can be activated via three 
pathways, the classical pathway (CP) that tackles antibody-antigen 
complex, gram-negative bacteria, apoptotic cells and some viruses 
(123, 124). The second pathway is via mannose binding lectin (MBL), 
which is directed to kill pathogens that expose mannose in their 
structure (123, 124). 
Finally, the alternative pathway (AP) destroys different sorts of 
contagious factors such as viruses, bacteria and fungi, as well as 
having a role in immune surveillance against tumours (123, 124). 
These pathways are linked into a common termination lane, leading to 
the formation of the membrane attack complex (MAC) (Fig. 1.7), this 
complex is amphipathic and composed of  C5b, C6, C7, C8 and 
several C9 molecules and causes lysis of the pathogen (123, 128, 129). 
In addition, many of the products generated during complement 
activation are able to opsonize damaged cells or pathogens to facilitate 
phagocytosis (130, 131) . Altogether, complement activation enhances 
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the ability of antibodies and phagocytic cells to clear invading 
pathogens and cellular debris from the circulation (132). 
Induction of the complement cascade through DAMPs and PAMPs or 
antibodies is a fundamental for pathogen elimination, humoral 
immunity development, homeostatic clearance of immune complexes 
and damaged cells, and cellular inflammatory event regulation (120, 
133). To be mentioned, a clear concept about complement interaction 
with some DAMPs like histones while clearing damaged cells has not 
been demonstrated yet.    
.  
 
Figure 1.7 The complement pathways converge into a common 
termination lane, leading to the formation of C5b-9 
MAC . 
 
Complement activation steps are monitored by many inhibitors, in 
order to achieve a balance between active detection and destruction of 
pathogens and reduction of bystander tissue damage (125). This 
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regulation occurs mainly at the convertase level, and through the 
assembly of MAC (134). 
In the face of the protective role that the complement system 
undertakes, it has been demonstrated that dysregulation or 
insufficiency of complement proteins can lead to many autoimmune 
and non-autoimmune diseases (123, 135) 
 
1.5.2 The development of Complementology 
More than one century ago, Hans Buchner first characterized the 
complement system as a heat-labile bactericidal component that exists 
in blood (136). Thereafter, Jules Bordet indicated that the bactericidal 
activity of serum can be reinstated upon the thermal activity 
destruction by adding fresh serum (135). Paul Ehrlich replaced the 
term”Alexine” system that was given by Buchner and Bordet with 
“Complement” (119, 137). Bordet and Gengou then designed the 
complement fixation test in 1901, a haemolytic assay that incorporates 
the erythrocyte lysis to determine the complement activation 
termination point; this fixation assay has been used potentially for 
many decades to discover the activation cascade and to unravel the 
protein-protein and protein-membrane interactions which occur in the 
complement system (124, 138, 139).  
In the following decades, pioneer complementologists like Louis 
Pillemer and Hans Müller-Eberhard recognized the key factors that 
are engaged in the classical (140, 141), alternative (142), and terminal 
pathways of complement (119, 143, 144). In the 1970s and 1980s, 
progress in complement studies started on a genomic basis, this 
included complement protein isolation and sequencing, cDNA and 
genomic clones and sequence yield (138, 139, 145, 146). In addition, 
work progressed in identification of cell-surface complement 
receptors as well as soluble and superficial complement regulators 
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(147, 148). Furthermore, the bridging role of complement to the 
adaptive immune response development was demonstrated (135, 149).  
The last 20 years has seen a great development in different aspects of 
the complement system, e.g. the role of complement in homeostasis 
and clearance of apoptotic cells has been disclosed (150). Moreover, 
the association between genetic variance (e.g. Factor H) of 
complement proteins and disease predisposition like age related 
macular degeneration (AMD) has been clarified. Despite the previous 
observation of MBL (151) and AP (142) pathways, better 
comprehension of those pathways took place recently. The exploration 
of the functions of the new MBL-associated proteases and ficolins 
(152), and proof of the direct role of properdin in AP activation (153) 
together have disclosed many aspects of the interaction patterns in 
those pathways. 
Although the complement factors in circulation are generally 
produced in the liver, it is now understood that most tissues and 
inflammatory cells like neutrophils and macrophages, are effective 
origins of complement factors (154-158). On the other hand, recent 
studies have shown the essential impact of complement deposition and 
anaphylatoxin-mediated signalling on active surfaces, which play a 
part in adaptive immune response initiation (159-161). Clinically, 
modification of complement activity for therapeutic purposes has 
developed, for example a monoclonal antibody, eculizumab, which 
inhibits complement at the C5 activation level is in clinical use (135, 
162, 163).  
1.5.3 The complement proteins: Array and dynamics 
In addition to the main proteins of the complement cascade (C1-C9), 
the whole complement network consist of fluid-phase, cell-surface-
associated and intracellular proteins that elaborate as pattern-
recognition molecules (PRMs), proteases and convertases, regulators 
and signalling receptors that collectively mediate immune surveillance 
and tissue homeostasis (130, 158, 164), (Table 1.1). This array of 
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complement proteins is arranged in a hierarchical structure of the 
proteolytic cascade which is initiated with danger molecule surface 
identification, thereafter the subsequent event which is the release of 
potent proinflammatory mediators (Anaphylatoxins), opsonization and 
ultimately the analysis of the target by MAC formation (125). 
Several complement proteins are zymogens which are disseminated 
safely through the body and activated at the site of inflammation in a 
triggered enzyme cascade pattern, whereby a vigorous complement 
response is induced from the amplification of the start-up proteins by 
regulated sequential enzymatic reactions (119, 165). 
Differently than many other enzymatic cascades, the complement 
system represents a more sophisticated pattern as it is based on the 
composition of consecutive activated protein fragments, which 
subsequently turn into convertases that cleave other complement 
proteins to form the terminal enzymatic complex (119, 165), these 
complexes maintain their stability and activity for a very short time as 
another form of  regulatory mechanism operates that the complement 
system adopts to control activation (119, 166). 
Generally, complement proteins are represented by a capital letter 
followed by a lowercase suffix that should be “a” or “b” in case of low 
and high molecular weight fragment respectively e.g. C5a & C5b 
(167), this nomenclature principle has one exception with respect to 
C2, where C2a refers to the larger fragment while C2b indicates the 
small one (167). All the nine proteins C1-C9 are numbered 
chronologically to the cascade events except C4 which is cleaved with 
C2 and before C3(167).  
On the other hand, some MBL and AP pathway unique proteins have 
variant logical nomenclature like MASPs and factor ”B” (167). To 
indicate enzymatically active components and protein complexes a bar 
is used above the name usually e.g.    , while inactivated 
complement proteins due to complements’ inhibitors function is 
indicated with a lower case prefix “i” like iC3b (167, 168). 
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Table 1.1: Summary of the Complement protein array, adapted 
from Janeway et al(165); Salvador-Morales et al(169);Leendert 
(167);Carroll et al(135) Ricklin et al (120); Bajic et al(166). 
Pattern Recognition 
Name Pathway Ligand 
C1q Classical e.g. IgG, IgM complexes 
MBL Lectin Carbohydrate moieties 
Ficolin-1,2,3 Lectin Carbohydrate moieties 
Properdin Alternative DAMPs, PAMPs, LPS 
Serine Proteases 
Name Pathway Function 
C1r Classical Cleaves C1s 
C1s Classical Cleaves C4,C2 
MASP-1 Lectin Cleaves MASP-2, C3, Pro-f-D 
MASP-2 Lectin Cleaves C2, C4 
C2 Classical, Lectin 
Part of C3/C5 convertases 
C4bC2a/C4b2C2aC3b 
fB Alternative 
Part of C3/C5 convertases 
C3bBb/C3b2Bb 
fD Alternative Cleaves fB in C3bB complex 
fI Alternative Inactivates C3b, C4b 
Regulators 
Name Pathway Function 
C1INH Classical, Lectin Serine protease inhibitor 
C4bp Classical C3 convertase decay  
CR1 Classical, Alternative C3 convertase decay 
FHL-1 Alternative C3 convertase decay 
DAF Classical, Alternative C3 convertase decay 
Signal molecules 
Name Pathway Function 
C4a Classical, Lectin Anaphylatoxin 
C3a Classical, Lectin, Alternative Anaphylatoxin 
C5a Classical, Lectin, Alternative Anaphylatoxin 
Membrane binding proteins and opsonins 
Name Pathway Function 
C4b Classical, Lectin Phagocytosis 
C3b Classical, Lectin, Alternative Phagocytosis 
iC3b Classical, Lectin, Alternative Phagocytosis 
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Functionally, this array of complement proteins in blood and 
interstitial fluids together supply the immune system with multi-
defence strategies upon activation (169), (Fig. 1.8). These include 
direct lysis of targeted surfaces through MAC assembly (C5b-C9), 
elicitation of an inflammatory response by potent pro-inflammatory 
anaphylatoxins and chemoattractants generation (e.g., C3a, C5a),  
opsonisation and removal of targeted surfaces via the opsonic 
complement fragments C4b, C3b, iC3b which bind to their 
corresponding complement receptors (CRs) on phagocytes like 
macrophages and neutrophils (170-172). The complement system has 
anti-inflammatory functions too, as it binds to immune complexes and 
apoptotic cells and helps in their clearance from the circulation and 
damaged tissues (119). 
 
Figure 1.8 Consequent functional implications of complement 
activation, C. Salvador-Morales et al (169). 
 
1.5.4 The “C4” component of the complement system 
Complement component C4 is a 203 kDa protein which serves as an 
essential part of the humoral immune response (173, 174). It can be 
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activated and cleaved by C1s and MASP2 serine proteases in the 
classical and lectin pathway respectively (174), such activation results 
in the generation of C4b (195kDa) and C4a (9kDa) (175). In addition 
to its role in opsonisation (175), the C4b fragment constitutes a 
subunit of the convertases C3 (C4b2a) and C5 (C4b2a.C3b), which are 
the enzymatic complexes that activate C3 and C5 of the classical and 
lectin pathways (130, 176), (Fig. 1.9).  
Whilst the anaphylatoxin role of C4 is still controversial (178), the 
dissociation of this fragment from C4 leads to significant 
conformational alteration in the C4b molecule which is supportive in 
both structural and functional aspects (176). 
C4 is produced as a single chain precursor protein that is cleaved 
enzymatically when secreted to form a triple chain molecule of around 
210 kDa molecular weight (176, 177). This ternary structure is 
composed of three different chains including α (~95 kDa), β (~75 
kDa) and γ (~33 kDa) which are linked by disulphide bonds (178). 
Despite sharing up to 30% sequence identity with C3 and C5, C4 is 
considered a much more sophisticated and developed protein because 
of the formation of the three chains and the display of 
posttranslational modifications including four N- and one O-linked 
glycosylations and sulphation of three tyrosine residues (175, 179), 
(Fig. 1.10). 
 
Figure 1.9 The function of C4 in the complement system: 
Proteolytic processing and function of C4 and C4b in the CP 
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(Including C1s) and the LP (including MASP-1 and MASP-
2). Active proteases are in bold font. C4b2a and C4b2a3b are 
the C3 and C5 convertases respectively, adapted from 
Mortensen et al (175). 
 
Figure 1.10 A scheme that displays the multi-chain structure of 
C4 and C4b. Four N-linked (N226, N862, N1328, N1391) 
and one O-linked (T1244) glycosylation sites are labelled, 
Mortensen et al (175). 
 
C4 concentration in body fluid is about 600µg/ml in serum  (177, 180) 
and 3.3 µg/ml in cerebrospinal fluid (181), while it is around 5.6 
µg/ml in tears (182). 
During complement activation C4a (anaphylotoxin, ~9 kDa) is 
cleaved off the N-terminal of the α chain producing C4b (192 kDa).  
Cleavage of surface-bound C4b by factor I forms the soluble C4c 
fragment (~146 kDa) and the cell-bound C4d fragment (~45 kDa) 
(176, 183, 184). Complement C4c is composed of the C4 β chain 
(~75kDa), the C4 γ chain (33 kDa) and two of the α chain fragments; 
an N-terminal 27 kDa fragment (C4cα27) and a 16 kDa C-terminal 
fragment (C4cα16).  These are linked by disulphide bonds as follows: 
C4β-S-S-C4α3-S-S-C4γ-S-S-C4α4(178).The structures of intracellular 
C4 precursor and the mature plasma form and its successive 
degradation molecules are represented in figure 1.11.   
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Figure 1.11 Polypeptide structure of intracellular prepro human 
C4 (above dashed line) and of mature plasma C4. For the 
latter, the polypeptide chain composition of its major 
activation and secondary degradation products are shown. 
Indicated are the N- and C-termini of chains, the sites of N-
linked glycosylation (closed circle), the site of O-
glycosylation (open circle), the thioester bond formed by the 
side chains of residues C1010 and Q1013, before and after 
transacylation to a hydroxyl nucleophile (ROH), the location 
of the isotypic cluster of residues and the sites of tyrosine 
sulphation. Only inter-chain disulphides are shown. The 
molecular masses indicated are for the polypeptide segments 
only; approximately 2 kDa should be added for each 
carbohydrate chain that is present, adapted from Isenman et 
al (178). 
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Complement C4 exists in C4A and C4B variants which share 99% of 
sequence and vary in six residues only, the plurality of individuals 
expresses both isoforms (174, 185) . C4A and C4B differ in their 
haemolytic activities and covalent affinity to antigens and immune 
complexes, in addition to variation in serological reactivity (176). The 
C4b fragment from C4B tends to create a covalent ester bond with 
substrates that contain hydroxyl groups; this occurs in a very rapid and 
active reaction (177, 186, 187). Contrariwise, C4A derived C4b 
efficiently forms a covalent amide bond with amino groups from 
antigens (177, 187). C4A is much less efficient than C4B in binding 
with hydroxyl group containing antigens (176, 188). This difference 
may lead to many functional variations between C4 isoforms, C4A is 
more likely to be beneficial for assuring antibody-antigen aggregate 
solubilisation, or prevention of immune precipitation by binding to 
antigens in immune complexes or to immunoglobulin G, while C4B 
propagates the activation pathways that result in the MAC formation 
to destroy invading antigens (176). This variant binding affinity 
between C4 isoforms is attributed to the variation in the C4d region of 
the alpha chain, a region that also specifies Rodgers (Rg) versus  
Chido (Ch) blood group antigenic determinants (176, 184, 189).  
Regardless of C4 isotype, formation of amide or ester bonds protects 
C4 against hydrolysis and stabilizes C4b on the surface of the 
pathogen, which in turn restricts the complement activity to the 
targeted site (187).  
Interestingly, this variability of C4 may make this protein more 
qualified to interact with some other molecules where the 
establishment of ester or amide bonds is possible. In the same vein, 
Pietrocola et al. have found that the domain C4b binds to what they 
called complement interfering protein (CIP) which is produced by the 
group B Streptococcus (GBS) (190). Furthermore, this interaction 
between CIP and C4b hindered the latter association with C2 and 
supposedly suppressed the formation of C3 convertase (C4b2C2a) 
which consequently decreased the CP and MBL complement activity, 
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where C4 is the main participant in these pathways (190).  In that 
sense, it seems a matter of importance to study the binding affinity of 
some molecules that show an inhibitory role to complement 
activation. From this point, it was interesting to investigate the binding 
affinity of histones to the complement proteins after I discovered their 
effects as complement activity suppressors; this can help to 
understand how extracellular histones affect immune responses in 
many histone-related medical conditions including sepsis which may 
contribute to developing a proper strategy of therapy in such clinical 
cases.  
 
  1.5.5 Complement pathways: Different starts, one terminal 
In general, complement system activation events occur via three 
common pathways including CP, LP and AP (191). However, recent 
researchers have found some other bypass pathways that cause non-
traditional complement activation (192-195).  
With regard to the classical pathway, the C1 protein multiplex 
prompts this pathway by binding to variant ligands including 
antibody–antigen complexes, pathogen surfaces, apoptotic cells and 
their derivatives, and poly-anionic structures (166, 196). This complex 
is composed from the pattern recognition subunit C1q which 
associates with tetrameric proteases C1r2C1s2 calcium dependent 
complex, in which C1s has high structural pliability that gives it many 
functional advantages (196, 197). When C1q binds to a ligand surface, 
detachment of C1r-C1s dimer pairs from the C1 complex leads to C1r 
auto-activation which in turn activates C1s (166, 197), the latter 
cleaves C4 and the subcomponent C4b thereafter binds with C2 to 
form the C3 convertase C4b2a after C2a is being generated via C1s 
activation (198). As a result of C4b2a enzymatic activity, C3 is 
cleaved to generate the anaphylatoxin C3a and the C3b molecule 
which also has opsonic activity binds to C4b2a to produce the C5 
convertase C4b2aC3b (199), the latter splits C5 into the powerful 
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anaphylatoxin C5a. Anaphylatoxins have different controlled 
functions such as provoking inflammatory mediator release, vascular 
permeability increase and smooth muscle contraction (200). However, 
unregulated anaphylatoxin release may lead to serious consequences 
(200, 201). The crucial role of the other fragment C5b is the initiation 
of MAC complex formation (C5b-9) to lyse cells via insertion and 
functional pore construction on the targeted cellular membranes (136), 
(Fig 1.12).   
 
Figure 1.12 Complement system overview: Pathway specific PRMs, 
interactions and subsequent activation cascade. Garred et al 
(202). 
 
Despite sharing most of the cascade events with the CP pathway upon 
C4 cleavage, the MBL activation pathway has a different initiation 
trigger with regard to the PRMs and antibody independent activation 
(166, 203).  
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According to the recent complement research, the lectin pathway 
PRMs are widely expanded to include MBL, collectin-10 (CL-10 or 
CL-L1), collectin-11 (CL-11 or CL-K1), ficolin-1 (M-ficolin), ficolin-
2 (L-ficolin) and ficolin-3 (H-ficolin or Hakata antigen) (202, 204, 
205). 
In general, these lectin pathway initiators are composed of two 
structures, one is the collagen-like triple helical that is linked to a 
second one which is the pattern recognition as well as the descriptive 
structure, whereby MBL, CL-10, and CL-11 refer to C-type lectins 
(206, 207) and ficolin 1-3 indicate fibrinogen like proteins (207, 208). 
The serine proteases MASP1-3 mediate the lectin PRMs function 
(152, 163, 209). 
Lectin PRMs are circulating in complex with zymogen MASPs (203, 
210), binding of this complex leads to activation of MASP1 which 
subsequently activates MASP2, and the latter is able to cleave C4 and 
C2 to form the C3 convertase and go through a similar cascade to the 
classical pathway (203, 204, 211). Albeit at a slow rate, MASP-1 can 
directly cleave C3 and stimulate the AP pathway (119, 136), while 
MASP3 has an antagonist effect versus MASP2 as a part of activity 
regulation (198). Both MASP1 and 2 can be autoactivated but MASP1 
can cleave C2 only (210, 212), hence MASP2 is a very important 
enzyme of the lectin pathway like the analogue C1s of the CP pathway 
(136). 
In comparison with the classical pathway, the lectin PRMs circulate in 
lower concentrations as compared to C1q (135), but they overwhelm 
the latter by their ability to bind sugar moieties and acetyl groups 
belong to a wider scope of invading microorganisms and 
carbohydrates on apoptotic/necrotic cells (135, 166). Despite the 
structural and functional similarity between MASPs and the serine 
proteases C1r and C1s, the recognition molecule C1q can associate 
with tetramer of proteases (2 C1r, 2 C1s), while MBL and the ficolins 
seem to bind only one homodimer of each MASP (135, 213).  
 
 
54 
 
The alternative pathway has both unique initiation and activation 
events, despite converging with CP and MBL pathways in terminal 
MAC formation. Furthermore, it is distinctive in the sense of being 
active constantly at low level, thus ready to tackle any infection 
quickly by the slow hydrolysis of C3 (Tick over) (203, 214). In the 
same distinctive way, this pathway is primed without the conventional 
PRMs in the CP and lectin pathways, while C3 itself plays the role of 
recognition molecule (136). 
 However, some molecules can initiate the AP pathway like properdin 
and P-selectin by recruiting C3 (H2O) and C3b to the cell surface, 
whereby they bind directly to the targeted cell surface and act as 
platforms for local AP pathway C3 convertase formation (135, 153, 
212), (Fig. 1.13). Nevertheless, a recent paper has challenged the idea 
of considering properdin as a PRM, suggesting that binding of this 
molecule happens only upon C3 activation for the known purpose of 
stabilising the AP C3 convertase (215). 
 
Figure 1.13 Platforms for AP pathway activation. (A) Properdin is 
released from activated neutrophils and is bound to the cell 
membrane where it recruits C3b to compose the alternative 
pathway C3 convertases. C5a then trigger additional 
 
 
55 
 
neutrophils which secrete more properdin. This stimulates a 
vicious cycle of neutrophil and complement activation. (B) 
Properdin released from neutrophils or in the plasma binds to 
activated platelets enhancing C3 (H2O) recruitment and 
complement activation. (C) Stimulation of endothelial cells 
with C3a, heme, or other agonists induces expression of P-
selectin. P-selectin contains CCP domains and binds C3b, 
promoting formation of C3 convertases that generate more 
C3a to stimulate cells, adapted from Merle et al (212). 
 
The view of properdin as a pattern recognition molecule is therefore 
challenged, and it is argued that properdin typically binds a 
complement-activating surface subsequent to C3b in order to stabilize 
the alternative pathway C3 convertase. 
On the other hand, many types of carbohydrate structures which exist 
on the surfaces of bacteria, yeast and multicellular parasites are 
considered activating surfaces for many C3b binding sites, whereby 
they initiate the AP cascade via direct binding with C3b (119, 198, 
203, 214).  
With respect to the tick over process, native plasma C3 goes through 
reversible structural alterations and displays the thioester-containing 
domain (TED) (135, 214). This domain is hydrolysed thereafter to 
form a C3b structural and functional like molecule C3 (H2O), the 
latter then undergoes conformational configuration and exposes a 
binding locus for Factor B (fB) (216, 217). 
 Factor D (fD) cleaves fB to release Ba, resulting in the fluid phase C3 
convertase C3 (H2O) Bb (136, 218), this complex is unstable and can 
be dissociated by the regulatory fH which allow fI to split C3b to iC3b 
(136). Yet, properdin has been shown to increase the stability of this 
fluid phase complex and form C3(H2O)BbP, which leads to a tenfold 
increase its half-life (153). In the absence of pathogen or other 
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activating surface, the C3b that is generated upon C3 convertase 
activity will be degraded (214).  
In case of activating surface availability, C3b binds covalently to the 
surface and is able to form new C3 convertase in the presence of 
factors B and D (119, 214). 
 Thus, C3b plays an important role in the ‘amplification loop’ 
mechanism which supports all of the pathways including the AP itself 
(198). For this reason, the AP pathway should be regulated firmly due 
to its potent role in rapid amplification and targeting host tissues for 
C3b deposition and subsequent complement-mediated destruction 
(214). 
Binding of the AP pathway C3 convertase C3bBbP to another C3b 
domain covalently will create C3bBbP3b, which is the C5 convertase 
of the alternative pathway (135). In general, these convertases are 
more potent when assembled on a solid phase such as the cell 
membrane as compared to the fluid phase (136). Upon C5 cleavage, 
the AP pathway shares the same terminal events with CP and Lectin 
pathways (167, 219). 
 
1.5.6 Bypass pathways 
Interestingly, it has been reported that complement and coagulation 
pathways overlap with each other (220) . The research work on 
interconnection between these two systems has developed a new term 
in this field that is called the “Extrinsic protease pathway” (220, 221).  
Accordingly, it was demonstrated that central coagulation factors such 
as thrombin, plasmin, FXa and FXIa can directly cleave C3 and C5 
(214), stimulating an AP pathway mediated complement activation, 
and generation of C5a which triggers a local inflammation (118, 222). 
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Moreover, it was shown that complement activation can up-regulate 
the coagulation system and this process is mostly localized at 
complement deposition sites (214). 
On the other hand, some coagulation system components like 
thrombomodulin can act as a down-regulator factor for complement 
activation via FI mediated C3b inactivation (126).  
One of the novel bypass mechanisms is intracellular complement 
activation; in which locally produced C3a and C5a activate T cells via 
binding to their particular receptors on these lymphocytes (223-225). 
Other bypass scenarios include direct cleavage of C3 by MASP-1, 
bypassing C4b2a (119, 226-228). It has been proposed that C1q or 
MBL binding with C3b protect against fI and fH down regulating role 
(193). However, these mechanisms are still under research. 
In the same vein, other C2 bypass pathways have been reported, in 
which C4 can form a hybrid classical/AP C3 convertase (C4bC3bBb) 
(229) or even enhance C3bBb fixation on tissues (230). 
Regarding C3 independent mechanisms, Huber-Lang et al have 
revealed that macrophage and neutrophil serine proteases can directly 
split C5 to its subcomponents bypassing the need of C3 (231). 
However, it is unclear whether such kind of interaction is sufficient to 
go through the terminal cascade and form C5b-9 or not. 
1.5.7 Complement system regulation 
The complement system cascade is orchestrated via many soluble as 
well as membrane bound regulators (120), where this occurs in a 
complex type of physiological process (232). Fundamentally, 
complement regulators protect the surfaces of entire host cells from 
complement targeting and activation (233).  
Since eliminating apoptotic particles and necrotic cells from the body 
is one of the complement system functions, in such cases complement 
regulatory proteins would permit complement activation to the extent 
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that it carries out this precise mission, in the sense of blocking any 
further cascade activation other than C3b surface deposition (131). 
Furthermore, even in case of the invasion of pathogens and their 
related derivatives, the complement cascade works in a tightly 
regulated manner (131). 
Soluble complement regulators are present in plasma and other body 
fluids, and include factor H, factor H-like protein 1 (FHL1), 
properdin, carboxypeptidase N, C1 inhibitor, C4BP, complement 
factor H-related protein 1 (CFHR1), clusterin, and vitronectin1 (233). 
Membrane-bound regulators include CR1, complement receptors, 
membrane cofactor protein (MCP; CD46), DAF (CD55), and CD59 
(131, 166, 232, 234, 235), (Table 1.2). 
As compared to membrane-bound regulators, the soluble ones exert 
pathway specific regulatory effects and inactivate either C3 or C4, 
while the membrane-bounded regulators can suppress both C3 and C4 
and act on all pathways generally (233, 236). These regulators act as 
cofactors and/or by accelerating the decay of the convertases (232, 
235). 
Dysregulation of the complement system can cause different 
pathological consequences, such as types of autoimmune diseases and 
infection onset (232, 237, 238). The aberrant complement activity that 
leads to such pathological consequences may due to genetic 
deficiency of complement proteins and subsequent activity reduction, 
or hyper-activation results from decrease in expression of complement 
down-regulators (135).  
Thus, it is vitally important that this system holds a proper balance 
between activation on pathogens and modified self-cells versus 
inhibition on intact host cells (232, 233). 
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Table 1.2 Complement regulators, Bajic et al (166).
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1.5.8 Complement function in health and disease 
1.5.8.1 Complement in health 
There is increasing evidence showing the novel roles that complement 
proteins have in the body, a matter that paved the way for interesting 
fields of translational research (122, 123). Complement proteins 
function in developmental, proliferative, and regenerative pathways in 
both injured and uninjured tissue (123, 239, 240), (Fig. 1.14). 
C3a and C5a contribute to hepatic regeneration by their function of 
signalling on cytokine and transcription factor expression (241, 242). 
In addition, complement proteins are also associated with the 
regeneration of bone, cardiac muscle and skeletal muscle, as well as 
neurons (243, 244). Thus, it became unambiguous that the 
complement system undertakes unconventional roles, as well as the 
traditional inflammatory functions (122, 243).  
 
Figure 1.14 Complement proteins take part in proliferative and 
regenerative processes in organs including bone, marrow, 
liver, and connective tissues. Rutkowski  et al (123). 
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1.5.8.2 Complement in disease 
The protective role of the complement system to the host as well as its 
several defensive and innate/adaptive immunological functions is now 
unambiguous (120, 125, 167, 245, 246). However, any disturbance in 
this system balance may lead to serious harmful effects, (Fig. 1.15). 
Disorganised complement activity may be due to several factors 
including excessive activation, insufficient regulation or/and 
complement component deficiency (135, 238, 247). 
 
 
Figure 1.15 Complement mechanisms of dysregulation, adapted 
from Harris (247). 
 
Complement hyper-activation with respect to duration or intensity is 
due to prolonged existence or overwhelming amounts of complement 
activators such as bacteria, yeasts and damaged host tissue, otherwise 
excessive complement activity may result from reduction of 
complement down-regulator expression (130, 135). Such over-
activation associates with many pathological and clinical conditions 
like multiple sclerosis, rheumatoid arthritis, IR, Alzheimer’s, asthma, 
chronic obstructive pulmonary disease (COPD), sepsis and hyper-
acute organ rejection (131, 135), where the intensive complement 
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response boosts the hyper-inflammatory events in a way that exceeds 
the initial trigger of destructive effects (130). 
In sepsis, complement seems to have a devastating influence in this 
disease despite being beneficial in the early stages (248). Complement 
and particularly C5a may lead to organ damage in late stages of sepsis 
by consumptive coagulopathy in cooperation with a burst of cytokine 
flow (135, 249). Consequently, C5a affects the immune cells and 
stimulates an uncontrolled coagulation by C5a mediated TF 
expression that results in the harmful impact which is seen in sepsis 
(131, 248, 250).  
Many approaches have been made regarding complement 
therapeutics, including C5 inhibition, pathway initiation prevention, 
attenuating the amplification loop and complement effector function 
blocking, (Fig. 1.16).  Administrating the C3 inhibitor compstatin to a 
baboon model of late-stage sepsis significantly saved organs and 
improved other clinical biomarkers, advocating the use of complement 
inhibitors as interventional drugs in the second stage of severe sepsis 
(251, 252). Moreover, Colley et al suggested that C5aR1 and C5aR2 
receptors blocking with monoclonal abs has therapeutics effects where 
C5a mediates the inflammation in sepsis, ischemia-reperfusion injury 
and similar inflammatory conditions (253). However, many factors 
still represent a challenge for anti-complement therapy including 
thorough comprehension of disease mechanisms, disturbing the 
delicate system balance, adverse effects and complement proteins 
concentrations (131, 247, 254).  
On the other hand, less complement activity can result primarily from 
genetic deficiency of complement proteins or may occur temporarily 
due to complement consumption via certain conditions like infection, 
injury or surgery (135, 167, 238). Deficiency of the early component 
of the CP in addition to C2 and C4 is often connected with SLE (131, 
255), whereas insufficient C3 causes bacterial infection susceptibility 
(256). The lack of the factors fI or fH leads to C3 deficiency-like 
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consequences, due to subsequent impaired iC3b generation and hence 
phagocytosis (135, 256).  Lack of MBL is linked to respiratory tract 
infections, while MASP2 deficiency results in recurrent infections 
(131).  Deficiency of fH and disorder of C3 tick-over may lead to 
renal diseases including typeII membranoproliferative 
glomerulonephritis and atypical haemolytic-uremic syndrome (aHUS) 
(257, 258), whereas properdin deficiency was found to increase 
Neisseria meningitides mediated mortality (259). C5-C9 shortage 
correlates with predisposition to neisserial infections and 
susceptibility to dextran sulphate sodium-induced murine colitis (135, 
260-262). Figure 1.17 shows several pathogenic conditions due to 
local or systemic complement disorders.  
 
 
 
Figure1.16 The complement drug development scheme. 
Complement-targeted drugs and drug candidates that are in 
preclinical or clinical development as of September 2017 are 
shown. This schematic was found depending on publications, 
conference abstracts and publicly available information on 
company websites. The main target is listed beside each drug 
name. In the preclinical part, drug candidates are ordered 
according to target, and their order does not reflect the stage of 
development. In the phase I through phase III parts, drugs are 
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ordered chronologically according to the start date of the 
clinical trial; only the ultimate advanced trial is reported for 
each candidate drug, Ricklin  et al (254). 
 
 
 
Figure 1.17 Major mechanisms of the pathogenic involvement of 
complement in systemic and local disorders. Even when 
the complement system is operating ordinarily, adverse 
activation can occur upon exposure to enormous amounts of 
pathogen, DAMP stimuli or foreign surfaces such as 
transplanted organs or biomaterials. In several chronic 
disorders, genetic alterations result in a systemic or local 
imbalance of complement that can lead to inflammation, 
thrombosis and tissue damage. Insufficient removal of 
apoptotic cells, debris or immune complexes due to clearing 
capacity of the complement system being overwhelmed or 
lack in complement components can prompt or aggravate 
autoimmune and neurodegenerative diseases. aHUS, atypical 
haemolytic uraemic syndrome; AMD, age-related macular 
degeneration; C3G, C3 glomerulopathy; CARPA, 
complement activation-related pseudo allergy; PNH, 
paroxysmal nocturnal haemoglobinuria; SIRS, systemic 
inflammatory response syndrome; SLE, systemic lupus 
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erythematosus; TMA, thrombotic microangiopathy. Ricklin  
et al (254). 
Substitution with fresh frozen plasma or either purified complement 
proteins like MBL or C1-INH is a reconstitutive strategy that been 
used to tackle the primary complement deficiency problem (167, 263, 
264). 
All in all, both too much and not enough complement lead to 
pathological consequences as this double edge sword like system is 
meant to be tightly regulated to keep the body safe (135, 265). 
 
1.5.9 Complement detection assays. 
In order to thoroughly evaluate the potency of the complement 
system, researchers have developed different methodologies that are 
based on three major parts, which are: Functional assays, complement 
analysis and the detection of activation products (Neoepitopes) (129). 
Haemolytic assays were used usually to estimate complement 
activation in the CP and AP pathways (169, 199, 266, 267). In the 
classical CH50 test, this method depends on the use of IgG antibody 
coated sheep erythrocytes (EA) which are lysed in serum diluted in a 
Ca
++
 and Mg
++
 containing buffer, as these ions are important for these 
pathways’ convertase stability (169, 268), the results are commonly 
represented as the reciprocal dilution of serum needed to lyse 50% of 
a fixed amount of EA (269, 270).  
AH50 is the corresponding test to detect the AP activity, it requires  
rabbit (RbE) or guinea pig (GpE) erythrocytes for AP activation in 
serum that is diluted in a buffer containing only Mg
++
 ions, while  
Ca
++
 ions should be chelated with EGTA to block the classical and 
lectin pathways which are dependent on both ions rather than Mg
++ 
only like the AP (129).  
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To be mentioned, the haemolysis assay has many limitations despite 
being readily carried out, these includes the short shelf-life of SRBCs, 
the inconsistent inter-lot performance of SRBCs, and the low 
sensitivity of the assay with regard to measuring the activation product 
such as C5a and SC5b-9 (169). 
Enzyme immunoassay (EIA) techniques are widely used in 
complement work. Initially, this method was first described by 
Zwirmer et al who found that many complement proteins could be 
deposited on an appropriate solid phase during complement activation 
including the terminal products (271).  
Thereafter, developing EIAs for inspecting the deficiencies of the 
classical and the alternative pathways was ongoing (272), to 
specifically activate an individual pathway, plates were coated with 
IgM, mannan and LPS to stimulate the CP, MBL and the AP 
respectively  (129, 273, 274).   
EIAs tests that include the three pathways were developed and they 
are commercially available nowadays (Wieslab Complement System 
Screen, Wieslab AB, Malmö, Sweden) (129, 275, 276). This assay has 
many advantageous features over the hemolytic assays, since it is 
easily implemented, does not rely on sensitized erythrocytes, 
comprises the three pathways and easy fP deficiency detection in the 
AP (129).  
Serum samples are used in this method to detect activation via 
detecting the complement cascade terminal product (MAC), by 
targeting the neoepitope of C9 with anti-C5b-9 abs (277), (Fig. 1.18). 
Other techniques to quantify complement activity via MAC detection 
or other earlier components and their activating products may include 
ELISA, cell-ELISA, flow cytometry, immunofluorescence assay 
(IFA) and Western blotting (275, 278-283). 
Zymosan is a polysaccharide prepared from the cell wall of actively 
growing yeast Saccharomyces cerevisiae (284, 285).  This molecule 
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has served as a mimic model for microbial recognition for many 
decades, and was incorporated in many innate immunity studies 
including stimulation of inflammatory mediator production, 
mechanisms of phagocytosis, and activation of complement deposition 
(132, 286, 287). 
 
Figure 1.18 EIA principle for assay of activation of the three 
distinct complement pathways (Wieslab Complement 
System Screen®). Adapted from Harboe et al (129). 
 
In respect of complement activation, zymosan has been used both in 
vitro and in vivo to activate CP, MBL and AP in several complement 
research studies (279, 288-293). Thus it represents a good choice to 
stimulate the complement system cascade and study the difference in 
the complement proteins levels or the total terminal activity versus 
different assigned conditions (279, 294). 
There are three types of epitope on a complement protein and its 
subsequent activation fragments, therefore the specificity of antibodies 
is a very important consideration while studying complement 
activation in the laboratory (129, 276, 295), (Fig. 1.19). 
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Selecting the proper type of anticoagulant is important while studying 
the complement activity in whole blood; the recombinant hirudin 
analogue lepirudin has been shown to be a suitable anticoagulant 
without adverse effects on complement as compared to other 
anticoagulants like EDTA (129, 296). 
 
 
 
Figure 1.19 Activation-dependent epitope specificity. Specificity of 
epitope is pivotal in studies of complement activation. Three 
distinct types of epitope on a complement component and its 
activation products detectable by monoclonal antibodies are 
indicated: “native restricted epitopes” which exist only in the 
native form of complement component; “activation 
independent epitopes” are present both in the native 
component and in the activation product, while “neoepitopes” 
are existent on activation products only. Adapted from 
Harboe et al (129). 
The patient’s complement profile which reflects the disease severity 
and the pathophysiological role of complement used to be variable 
(235, 277, 283). Consequently, complement tests have an important 
role in the disease fellow up, monitoring complement-targeted therapy 
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as well as the initial disease diagnosis (277). Figure 1.20 displays the 
recent complement diagnostic approaches. 
 
 
Figure 1.20 Overview of major classes of complement diagnostic 
approaches, In addition, to the methods shown here, genetic 
analyses become increasingly prevalent in the complement 
diagnostics field. Ricklin et al (277). 
 
1.5.10 Complement role in innate immunity and phagocytosis 
The complement system represents an old arm of innate immunity that 
bridges the adaptive immune response and has expanded to cross talk 
with other systems such as coagulation (119, 220, 297).  
Consequently, this sophisticated network of interactive proteins has 
association with many events of the innate immune system including 
direct killing of pathogen by MAC, inflammatory response 
stimulation via its active anaphylatoxins and phagocytosis, whereas 
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the latter is the indirect strategy that the complement mediates to clear 
pathogens (114, 298). 
Phagocytosis is a receptor-mediated, actin and ATP-dependent 
mechanism that is stimulated via binding between the targeted surface 
antigens to the membranous receptors of the phagocytes like 
macrophages, dendritic cells and polymorphonuclear leucocytes (299, 
300).  
There are two types of phagocytes receptors, non-opsonic receptors 
that can straightway recognize the targeted surface like PAMPs, the 
other type is TLRs that help with other receptors in the uptake of a 
target and the phagosome modulation (301, 302). The Opsonic 
receptors are the other main type of phagocytosis associated receptor; 
they include the heterogeneous binders of the Fc region of 
immunoglobulins as well as the complement receptors like CR3 which 
are able to distinguish complement coated particles (301-303). 
Opsonisation is a vital mechanism to enhance phagocytosis and helps 
in efficient pathogen clearance (304), where an opsonin like C4b, 
C3b, iC3b act as adaptors that bind and activate potent phagocytic 
receptors (305), (Fig. 1.21.A).  
The process of phagocytosis is basically performed to internalise and 
engulf large particles (≥0.5µm), microorganisms, and cell debris then 
to degrade them and eventually present peptides derived from 
particulate antigens (306-308). Binding of a targeted particle-opsonin 
complex to one of the phagocytes’ opsonic receptors stimulates the 
rearrangements in the actin cytoskeleton which results in the 
internalization of the opsonised particle (132, 307).  
The term “Efferocytosis” refers to the process where apoptotic cells 
are scavenged by phagocytes (309). Some structural rearrangements 
accompany phagocytosis including membrane deformation, phagocyte 
pseudopod expansion, and their subsequent contraction to ingest 
particles and form an endocytic vesicle known as a phagosome (300, 
310, 311).  Microbes and apoptotic cells submit to variant oxygen 
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dependent and independent processing upon being ingested inside the 
phagosome (302, 305).  
Pathogen breakdown results in further ligand release which is detected 
by receptors on phagolysosomal membrane or in the cytosol, a matter 
that stimulate the inflammatory response, while the expression of 
digested bacterial peptides on the active phagocytes’ major 
histocompatibility complex class II enhances acquired immunity (305, 
312).  
In addition to the effect of complement activating products (C4b, C3b 
and iC3b) on phagocytosis via opsonisation (172, 313), the release of 
anaphyltoxins C3a and C5a contributes to phagocytosis triggering by 
recruiting more phagocytic cells to the inflammation site which 
promotes the uptake and destruction of pathogens by phagocytic cells 
(165, 172, 199), (Fig 1.21.B).  
Several assays have been developed in order to evaluate 
opsonophagocytic potency and are used in vaccine production by 
testing whether the vaccine-induced antibodies drive efficient 
complement deposition and subsequent opsonophagocytic killing 
(314-316).  
Thus, any disorder in complement activation kinetics or interference 
with complement opsonic molecules may lead to impacts on 
complement mediated phagocytic function and host defence (317, 
318), which is a vital mechanism of rapid immune defence since 
opsonisation via complement molecules can occur even before the CP 
that relies on antibodies and mounting of an adaptive immune 
response (172). 
 
A 
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Figure 1.21 Effects of complement activation on phagocytosis. A: 
Phagocytosis enhancement via opsonisation. B: Activation 
products like C3a and C5a recruit more phagocytes and 
trigger the phagocytosis process by binding to the N-terminal 
regions of granulocytes including the phagocytic cells. 
Dunkelberge et al (125). 
B 
A 
B 
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1.5.11 Hypothesis of the proposed work and aims 
The role of extra-cellular histones in inflammation and tissue injury 
was established well in several diseases, whether they are part of 
neutrophil extracellular traps NETs or necrotic cell debris (31, 35, 37, 
39) 
Little research has demonstrated the relationship between histones and 
the complement system which is the part of innate immunity that 
tackles both PAMPs and DAMPs, Leffler et al. reported NETs as 
potent complement activators and clarified that this interaction may 
have a main role in SLE, targeting complement with inhibitors or by 
elimination of complement activators like NETs could be 
advantageous for SLE patients (319). Bosman et al. found that 
complement activation via C5aR and C5L2 triggers the release of 
nucleosome components such as histones, resulting in a cycle of tissue 
injury and inflammation (55).  
 
On the other hand, other studies linked complement activity alteration 
to some other microbial protein secretion interference (190), they 
revealed that some microbial products are able to reduce complement 
activation and cause further innate immunity impairment (320). 
 
Recently, the group used a pull-down assay and found that histones 
interact with complement C4. We hypothesize that histones may affect 
the complement activation and subsequently affect phagocytosis.  
Therefore, the aim of my study was to 1: Demonstrating the binding 
affinity pattern between histones and C4 through different tests and 
under variant conditions (denatured and physiological) 2: Investigate 
the potential effect of histones bound C4 on complement activation 
and related phagocytosis. 
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Chapter 2: Extracellular Histones Show High Binding Affinity to 
Component C4 
2.1 Introduction 
The Complement system forms a major part of the host response to 
infection and cellular injury (130, 131). This system is intricately 
involved in these processes and  consists of a cascade of more than 50 
proteins, participating in three activation pathways; namely the 
classical (CP), mannose binding lectin (MBL) and alternative 
pathways (AP) (131). The classical pathway recognises antigen-
antibody complexes contained on the surface of pathogenic factors, 
including gram-negative bacteria, viruses and damaged cells (321). 
The MBL pathway binds mannose containing pathogenic surfaces 
(322). Finally, the alternative pathway directly targets surface 
carbohydrate regions on pathogens such as viruses, bacteria and fungi 
(323). 
These pathways are linked into a common termination pathway, 
leading to the formation of the membrane attack complex (MAC), this 
complex is amphipathic and composed of  C5b, C6, C7, C8 and 
several C9 molecules and causes lysis to the pathogen (123, 128, 129). 
Although the complement factors in circulation are generally 
produced in liver, it is now understood that most tissues and 
inflammatory cells like neutrophils and macrophages, are effective 
origins of complement factors (154-158). On the other hand, recent 
studies have shown the essential impact of complement deposition and 
anaphylatoxin-mediated signalling on active surface, which leads to 
adaptive immune response propagation (159-161) 
Many products generated during complement activation are also able 
to opsonize damaged cells or pathogens to facilitate phagocytosis 
(130, 131). In this way, complement activation enhances the ability of 
antibodies and phagocytic cells to clear invading pathogens and 
cellular debris from the circulation (132). 
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Complement activation not only kills pathogens but also damages host 
cells during an inflammatory reaction and excessive activation 
contributes to inflammation-driven tissue injury (324).  Host cell lysis 
will release cell breakdown products, including DNA and histones, 
and those damage-associate molecular patterns (DAMPs) have been 
demonstrated to play important roles in disease progression and host 
immune response (14, 325, 326). Histones, the most abundant and 
important DAMPs, can be detected in blood taken from many critical 
illnesses, such as severe trauma (35), severe sepsis (34, 37) and 
necrotising pancreatitis (327). 
Histones are positively charged proteins and have high affinity for 
negatively charged phospho-groups in DNA or cell membranes. 
Normally, they are highly alkaline intra-nuclear proteins that are 
present in eukaryotic cells (20). The basic function of these nuclear 
proteins is to pack and sort the DNA into functional units 
(Nucleosomes) as well as gene regulation (24). Misplaced histones in 
the extracellular space can display a toxic and pro-inflammatory 
distressing side both in vitro and in vivo (34), this happens when they 
are released passively or actively by dead or triggered cells (20, 35). 
Furthermore, extracellular histones represent a cell death alarm that 
stimulates the immunological response as well as the body repair 
programme (36). Histones are also released through neutrophil 
extracellular traps (NETs), these traps have a significant protective 
role against exogenous pathogens (25, 26). 
Histone binding to cell membranes allows ions, particularly Ca
2+
 
influx into cells to cause harmful effects to cells contacted (35). In 
addition, histones are also the ligands of Toll-like receptors (TLR)-2, 
4 and 9 receptors to trigger immune response; including 
inflammasome activation and cytokine release (54, 62, 66). 
Histones also interact with coagulation factors in the circulation to 
promote thrombin generation, fibrin precipitation and systemic 
coagulation activation (40, 61, 63, 71, 328). In animal models, 
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extracellular histones have been shown to mediate multiple organ 
injury and even death in sepsis (34, 329).  Clinically, correlation 
between circulating histone levels and organ injury as well as disease 
severity has also been demonstrated (37).  
Recently, we found that extracellular histones interact with 
complement component 4 (C4) protein. Complement C4 coded by 
both C4A and C4B genes is synthesised into a single peptide 
(Precursor) and then cleaved into α (98kDa), β (73kDa) and γ (33kDa) 
chains (176, 330).  Upon complement activation, C4 is cleaved by the 
C1s enzyme into C4a and C4b, the latter mainly participates in 
classical and lectin pathways by forming C3 and C5 convertases, 
whilst C4a as an anaphylatoxins enhances smooth muscle contraction, 
histamine release and vascular permeability as well as serving as a 
chemotaxis and inflammatory mediator (331, 332).  
In many disease conditions, particularly in sepsis, complement 
activation (333) and histone release (37) coexist. The outcome of 
histones binding to C4 appears important and this study is aiming to 
understand the pathophysiology related to the complement system and 
extracellular histones. 
 
  2.2 Materials and Methods 
2.2.1 Human plasma and serum 
Citrated plasma and serum were isolated from whole blood drawn 
from critically ill patients according to the protocol granted by 
Liverpool Adult Ethical Committee (Ref: 13/NW/0089). Normal 
human serum was purchased from CompTech, USA. 
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2.2.2 Fractionation of human serum and plasma by 
ultracentrifugation 
Citrated plasma and serum (1 ml) from patients were fractionated by 
ultracentrifugation at 274,400 x g (4°C) for 1 h and then six layers of 
equal volumes fractions (166 µl/fraction) were collected. Histones and 
Histone-DNA complexes were then measured in each fraction by 
Western blot and ELISA (Cell Death Detection ELISA PLUS; Roche, 
West Sussex, U.K.), respectively, as previously described (35). 
 
2.2.3 Isolation of histone binding protein from plasma and mass 
spectrometry analysis 
Isolated citrated plasma was diluted 1:2 with phosphate buffered 
saline (PBS) (v/v) and centrifuged to eliminate insoluble contents.   
The harvested supernatant was then pre-cleared using blank Sepharose 
resin and then loaded on CNBr-activated Sepharose 4B (GE 
Healthcare, Little Chalfont, UK) column conjugated with calf thymus 
histones (Roche, West Sussex, UK). After a high stringency wash 
with PBS+0.5% (v/v) Tween-20 (Sigma-Aldrich, Dorset, UK) 
followed by PBS, histone-binding proteins were eluted and separated 
by gel electrophoresis.  Gel slices from SDS-PAGE were washed (2 x 
30 min) with 50% acetonitrile, 0.2M ammonium bicarbonate pH 8.9 
and then dried in a rotary evaporator. The slices were re-swollen in 
rehydration buffer RHB [2 M urea, 0.2 M ammonium bicarbonate pH 
7.8] containing 0.2 μg trypsin and incubated at 37ºC overnight. Excess 
RHB was then removed and peptides were extracted from the gel 
slices with 60% acetonitrile, 0.1% TFA. The total peptide extract was 
concentrated in a rotary evaporator and then desalted using C18 
ZipTips according to the manufacturer’s instructions. MS analysis was 
performed using a MALDI-Tof instrument (Waters-Micromass) using 
a saturated solution of alpha-cyano-4 hydroxycinnaminic acid in 50% 
acetonitrile/0.1% trifluoroacetic acid.  
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2.2.4 Detection of Histone-C4 complexes by ELISA 
Histone-C4 complexes were detected in normal and critically ill 
patient plasma by modified Cell death detection ELISA PLUS 
(Roche) with modification. In brief, normal plasma was pre- incubated 
with different concentrations of histones for 10 minutes prior to 
ELISA, allowing for histones to bind to C4 within the plasma.  
For the ELISA procedure, diluted plasma was incubated for 2 hours at 
room temperature with a biotinylated-histone capture antibody, in 
streptavidin coated 96 well plates (Cell death detection ELISA PLUS, 
Roche). Samples were washed and subject to sequential 1 hour 
incubations with anti-human C4 abs (Abcam) and anti-rabbit-HRP 
antibodies. Histone-C4 complexes were calculated in normal and 
patient samples (arbitrary units; AU) based sample absorbance 
(450nm), compared to those of the standard curve. 
 
2.2.5 Gel overlay assay with C4 and histones individually 
Equal molar concentration of H1, H2A, H2B, H3 and H4 besides 4µg 
of S100P (as a control) were loaded into a 15% SDS-PAGE gel then 
subjected to Western blotting with 0.5µg of C4 and 4µg of S100P 
which is the  negative control. Upon the transfer, each histone’s 
membrane was overlayed overnight at 4˚ C with overlay buffer 
containing the corresponding concentration of the recombinant histone 
(H1, H2A≈1.6µg/ml, H2B, H3 and H4 ≈1.26µg/ml). Later, particular 
anti-histone abs were used to detect the band of each overlay histone 
that might bind to the loaded C4. Recombinant histones (Produced in 
an E. coli strain) were purchased from New England Biolabs 
(Massachusetts, USA), while the anti-histone abs and anti-C4 abs 
were made by Abcam (Cambridge, UK). C4 was purchased from 
Fitzgerald, USA. 
Another experiment was designed to verify the binding affinity of 
each type of histone to C4. Four microgram of S100P and equal molar 
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concentration of H1, H2A, H2B, H3 and H4 in addition to 0.25µg of 
C4 were used in a 15% twin SDS-PAGE gels for the overlay assay 
and Coomassie staining. The membrane was overlayed with 10µg/ml 
of C4 at 4˚ C overnight then incubated with anti-C4 abs. 
 
2.2.6 Western blotting using HRP conjugated C4 
To avoid the possible effect of antibodies, HRP-conjugated C4 was 
used to confirm the interaction between complement C4 and 
individual histones.  Two µg of H2A, H2B, H3 and H4, 4 µg of H1 
and 6 µg of S100P (as control) were subjected to Western blotting 
with HRP-conjugated C4 protein. Another identical gel was stained 
with Coomassie blue to demonstrate the equal loading. C4 protein was 
purchased from Fitzgerald, USA and conjugated to HRP using a 
Lighting-Link HRP conjugation kit (Innova Bioscience, Babraham, 
Cambridge, UK, ref. 701-0000) according to the procedure 
recommended by the manufacturer. The HRP-conjugated C4 was used 
to incubate the membrane at 4˚ C overnight and the bands were 
visualized using enhanced chemiluminescent (ECL) substrates 
(Thermo Fisher Scientific, USA).  
 
2.2.7 Production of complement C4 Beta chain domains for gel 
overlay assay 
2.2.7.1 Plasmid design and Production 
In order to have a greater chance to get the desired protein, C4 beta 
chain production involved generating two domains which altogether 
form that protein, to eliminate a higher molecular weight protein 
production problem. Thus, Beta chain production work included the 
synthesis of recombinant proteins C4 1-3 and 4-5 by E coli (334), 
(Fig.2.1).  
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Figure 2.1 Peptide sequence of Complement C4 beta chain. 
Domain1-3 starts from no.20 and ends at the amino acid 
no.365 (Highlighted with light blue), while the rest of C4 β 
fragment (Domain 4-5) starts and ends at 416 and 725 
amino acids respectively (Highlighted with yellow). 
Adapted from UniProt. 
 
 
Domain 1-3 
Domain 4-5 
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In summary, the peptide sequence was obtained from UniProt. The 
coding DNA sequence was then translated from peptide sequence and 
synthesised (335). A pET expression system was used for plasmid 
construction and proliferation (336). C4 domains 1-3/4-5 were sub-
cloned individually into a pET-16b vector in an expression system that 
contains a T7 promoter and ampicillin resistant marker, as well as a 
His10-tag. The pET-16b-C4 domains expression constructs were 
sequenced to confirm the right coding sequences subcloned.  The 
maps of these constructs were generated (Fig. 2.2.A and B) using 
SnapGene
®
. 
The detailed procedure is as following: the coding DNA for human C4 
beta chain 1-3 and 4-5 domains were synthesised by life technology 
containing BamHI and NdeI restriction sites. The DNA was amplified 
using polymerase chain reaction (PCR), extracted by QIAquick Gel 
Extraction Kit (QIAGEN, Netherlands) and digested with NdeI and 
BamH1 restriction enzymes as inserts. Ten µl of pET16 (b+) DNA 
was also digested using the same enzymes as vector. The digested 
pET-16b vector (Novagen, Germany) was ligated with inserts using 
T4 DNA ligase. After transformation into DH5α competent cells, 
resultant single clones were cultured and plasmid DNAs were isolated 
using QIAprep Spin Miniprep Kit and checked using NdeI and 
BamH1 digestion.  Plasmids containing the correct sizes of DNA 
inserts were subsequently sequenced for confirmation. The correct 
plasmids were transformed into Shuffle® T7 and BL21 (DE3) E. coli, 
to express domain 1-3 and domain 4-5 peptides respectively.  
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Figure 2.2 Plasmids for C4 domains expression. DNA of C4 
domain 1-3 (A) as well as C4 domain 4-5 (B) were digested 
with BamHI and NdeI and ligated to pET-16b vector to form 
a novel plasmid for each C4 fragment production.  The 
digested domains were subjected to an 1 % (w/v) agarose gel 
and showed identical base pair bands.  
 
 
2.2.7.2 Protein induction  
2 µL of each domain plasmid was transformed into Shuffle® T7 
express E. coli and BL21 (DE3), for the production of C4 domains 1-3 
and 4-5 respectively. The following day, single colonies were selected 
and each incubated in 3 mL LB broth containing 100 µg/mL (w/v) 
ampicillin for 1 h at 37°C. Bacteria were then induced at 18°C 
overnight with 1 mM IPTG (Melford, UK), with a non-induced colony 
acting as negative control. After incubation, a sample of 30 µL was 
analysed by 15% SDS-PAGE. Once the small scale induction was 
successful, a large scale induction was conducted. Bacteria were 
continually incubated in 500 mL LB broth containing 100 µg/mL 
ampicillin at 37°C and the bacteria optical density (OD600) measured 
at 600 nm until reaching an OD reading of between 0.5 and 0.6. The 
bacteria were subsequently induced at 18°C overnight. Proteins from 
the non-induced and induced bacteria were then run on a 15% SDS-
PAGE gel, (Fig. 2.3). 
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Figure 2.3 β chains domains induction. Domain 1-3 (Upper panel) 
and  domain 4-5 (Lower panel) expression plasmids were 
transformed to T7 and  BL21 E. coli  respectively,  then 
induced at 18°C with 1 mM IPTG overnight. The non-
induced E. coli was used as negative control.  
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2.2.7.3 Protein purification using a Nickel-Nitrilotriacetic acid (Ni-
NTA) resin (QIAGEN, USA) column 
After large scale induction, bacteria were harvested at 6,000 × g for 10 
min at 4 °C. The pellet was resuspended in lysis buffer (50 mM Tris-
HCl, pH 7.4, 500 mM NaCl, 10mM imidazole and 5% glycerol). 
Upon a 30 min of centrifugation at 25000 g, the remaining pellet was 
resuspended with denaturation buffer (8 M urea, 40 mM Tris-HCl, 
pH7.4) and sonicated eight times for 30 seconds with a rest period of 1 
min through each sonication. Next, the sonicated yield was spun down 
again and the supernatant was diluted with ddH2O that time. In order to 
identify the desired proteins, each supernatant was run on a 15% SDS-
PAGE gel.  
For C4 domains denaturation purification, the denatured inclusion 
bodies were applied to a Ni-NTA resin (QIAGEN, USA) column, pre-
equilibrated with the denaturation buffer (4 M urea, 20 mM Tris-HCl, 
pH 8. 20 ml of the supernatant was passed through the column, then 
many buffers were used to wash the column including (Denaturation 
buffer+30 mM imidazole), (Denaturation buffer+10 mM β-
mercaptoethanol), (20 Mm Tris-HCl pH 7.4, 100mM NaCl with then 
without 5 mM β-Cyclodextrin). Finally, the C4 domain was eluted and 
refolded by 20 Mm Tris-HCl pH 7.4, 100mM NaCl+300 mM 
imidazole). A sample of 30µl of each domain elution was loaded into 
a 15% SDS-PAGE gel. Thereafter, the proteins were buffer exchanged 
and concentrated using Thermo Scientific™ Pierce™ Protein 
Concentrator tubes. 
 
2.2.7.4 SDS-PAGE and Coomassie brilliant blue staining 
Proteins were loaded into 10 – 15% SDS-PAGE gels and subjected to 
electrophoresis at 30 mAMP/gel for 1 h. Following electrophoresis, 
the gels were stained using Coomassie brilliant blue staining buffer 
containing 0.25% (w/v) Coomassie brilliant blue, 10 % (v/v) acetic 
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acid and 30% (v/v) methanol for 30 min at room temperature, as 
described (337). After staining, the gel was destained with 10% (v/v) 
acetic acid and 30% (v/v) methanol for 6 hours, changing the 
destaining buffer four times, (Fig.2.4). 
 
 
 
 
Figure 2.4 C4β chains domains purification. Domain 1-3 as well as 
4-5 were insoluble, the inclusion bodies were denatured in 
urea and refolded on Ni-NTA resin column. 15% SDS-PAGE 
was loaded with serial concentrations of C4β 1-3 (Left panel) 
and 4.5 (Right panel).  
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2.2.7.5 Determination of produced protein concentrations 
The concentration of purified proteins was tested using a DC™ 
Protein Assay (Bio-Rad, USA) and the Quick Start™ BSA standard 
set (Bio-Rad, USA) referring to the instruction manual. In addition, 
the Nanodrop ND-1000 Spectrophotometer (USA) was also used for 
calculation of the C4 domain concentrations using OD readings at 280 
nm (338). 
 
2.2.8 Gel overlay assay for C4 beta chain domains 
This method was used to detect the binding affinity of C4 domains to 
H3. In brief, a 15% SDS-PAGE gel was loaded with 2µg of 
recombinant H3 (New England Biolabs, Massachusetts, USA), 4µg of 
S100P that was produced by me as a negative control, 0.5µg of C4 β 
chain domains 1-3, 4-5 and the same amount of full length C4 
(Fitzgerald, USA) was loaded in the last well. Upon electrophoresis 
and transfer, the procedure was resumed as previously described (75) 
and the membrane was overlayed with around 1.26µg/ml of the 
recombinant H3 at 4˚C overnight. Thereafter, bound H3 was detected 
by anti-H3 antibodies (Abcam, Cambridge, UK).  
 
2.2.9 Surface Plasmon resonance measurements 
The binding parameters of C4 to individual histones, including the 
equilibrium dissociation constant (KD), affinities on-rates (kon), and 
off-rates (koff) were measured by surface plasmon resonance analysis 
on a Proteon XPR36 system (Bio-Rad) in collaboration with the 
University of Manchester. Chips coated with 20µg/ml streptavidin 
(GLH, GE Healthcare), which could directly interact with histones 
(339),  were used for immobilizing individual histones and measuring 
binding affinities to C4. Running buffer (10 mM HEPES pH7.4, 150 
mM NaCl, 0.05% Tween 20) and regeneration buffer (0.1 M glycine 
pH2.2) were used throughout the assay. Five µg/mL of each 
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recombinant histone (H1, H2A, H2B, H3 or H4) in running buffer was 
captured only on the surface of flow cells Fc (2-6) with Fc1 set as 
blank. For kinetics, a concentration series of C4 was injected at a flow 
rate of 10µl/min over both captured histone surface and reference 
surface (blank) at 20
o
C. KDs were calculated using software provided 
by the manufacturer.  
 
2.2.10 Statistical analysis 
Intergroup differences were analyzed using ANOVA followed by 
Student–Newman–Keuls test. Two group comparisons with or without 
treatment used Student t test unless otherwise specified. P<0.05 was 
considered statistically significant. 
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2.3 Results 
2.3.1 Free histones exist in circulation and can form complexes 
with complement C4 
It is known that nucleosomes could be released actively from dying 
cells or passively through neutrophil extracellular trap formation and 
degraded into histones and DNA (27, 340-343). Nevertheless, it is not 
obvious if circulating histones are still in the form of histone-DNA 
complexes exclusively. Using ultracentrifugation to fractionate plasma 
or serum with high levels of circulating histones into six fractions, we 
found that histones were detectable in all the six fractions (Fig.2.5, 
upper panel), but DNA-histone complexes (most likely nucleosomes) 
were precipitated in fraction 6 only (bottom fraction) (Fig.2.5, lower 
panel). No difference was found between plasma and serum. This 
experiment demonstrated that DNA free histones exist in circulation 
and they themselves can play the role as damage associate molecular 
patterns DAMPs upon release as demonstrated by many previous 
publications (35, 37-40). 
 
 
Figure 2.5 Histones can exist in the circulation in a free form. 
Critically ill patient plasma was separated into 6 fractions (1 
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= upper fraction; 6 = lower fraction) based on density using 
ultracentrifugation. Circulating histones (top panel) were 
measured by Western blot and histone-DNA complexes 
(bottom panel) quantified by ELISA (n=4). 
 
Histone-conjugated Sepharose beads were used to pull down human 
plasma proteins. Following extensive washing, proteins bound to 
histone-beads were eluted. Multiple proteins were visualised on 
Coomassie blue stained gels with two major protein bands at 
approximately 70 kDa and 25 kDa (Fig. 2.6.A). Following liquid 
chromatography-mass spectrometry (LC-MS/MS) analysis, 
complement C4 and C-reactive protein (CRP) were identified (Fig. 
2.6.B and C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
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Figure 2.6 Identification of histones bound C4 as well as CRP in 
pulled down human plasma proteins. (A) Using histone-
conjugated Sepharose, a few proteins were pulled down. 
Among them, there were 2 major bands on Coomassie blue 
stained gel, one was complement C4 and the other was 
CRP, as identified by mass spectrometry. (B and C) The 
typical spectra of the two major proteins are presented. 
 
CRP was reported to be a major histone-binding protein to 
neutralising histone toxicities (75). Using ELISA kit, we then found 
that histone-complement C4 complexes were detectable in normal 
plasma spiked with calf thymus histones, and were proportional to the 
increase of histones concentration (Fig. 2.7.A).  Histone-complement 
C4 complexes were also existent in critically ill patients’ plasma that 
have high levels of circulating histones (Fig.2.7.B), with a significant 
difference as compared with normal plasma. This data confirmed that 
histones form complexes with C4 in vivo.  
The previous outcomes were encouraging enough to further study the 
interaction pattern between histones and C4 to highlight the structural 
C 
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engagement between these two types of proteins and verify it using 
different assays as will be explained later.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7 Identification of complement component 4 as a histone 
binding protein. (A) Histone-C4 complexes were detected by 
ELISA following the addition of different concentrations of 
histones to normal plasma. (B) Histone-C4 complexes are 
elevated in critically ill patient plasma compared with normal 
plasma. (n=3), *p < 0.001 compared with normal subjects. 
 
A
A 
B 
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2.3.2 Individual histones show binding affinity to complement C4 
through different assays 
To determine the relative binding extents of individual histones to C4, 
equal molar concentrations of individual histones were subjected to 
gel overlay assay accompanied with Coomassie blue stained gel to 
demonstrate equal loading.  
In this experiment, each membrane was overlayed with one type of 
histones and then C4-histone band was targeted with anti-histone abs 
for that type of histone. It was shown that there was an engagement 
trend between histones and C4 which seems mainly with the β chain 
(~75 kDa) of  C4 (Fig. 2.8. A, B, C, D and E),  
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
C4 β  
C4γ 
B 
C4 β  
C4γ 
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Figure 2.8 Individual histone shows binding affinity to C4 mainly 
through its β chain. (A, B, C, D and E) Five pairs of 15% 
SDS-PAGE gels were loaded with 0.25µg of C4, 2µg of 
C 
C4 β  
C4γ 
E 
C4 β  
C4γ 
D 
C4 β  
C4γ 
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certain histone type and 6µg of the negative control S100P. 
Following the electrophoresis step, one gel  of each pair was 
stained with Coomassie while the other copy was transferred 
onto polyvinylidene difluoride membrane, then overlayed with 
one of the histone proteins before probing with the abs which 
are specific for that type of overlayed histone. 
. 
To determine the comparative binding strengths under physiological 
conditions, I used surface plasmon resonance (SPR, Biocore X-100) in 
collaboration with the University of Manchester. Calf thymus histones 
immobilized on the surface of a streptavidin coated chip was 
incubated with soluble human C4 concentrations ranging from 0.04 to 
0.5µM. The histones’ proteins bound to C4 in a dose-dependent 
manner, (figure 2.9.A-E).  
 
 
 
 
 
 
 
 
 
 
 
 
B 
A 
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Figure 2.9 The response by time (-60 - 120S) to different 
concentration ranges of native complement component C4 
to each histone in RU. (A) Ligand, 5µg/ml H1, analyte C4 
0.5- 0.03125µM two folds serial dilutions. (B) Ligand, 5µg/ml 
H2A, analyte C4 1.000- 0.063µM two folds serial dilutions.   
(C) Ligand, 5µg/ml H2A, analyte C4 1.000- 0.063µM two 
folds serial dilutions. (D) Ligand, 5µg.ml H3, analyte C4 
0.063- 0.004 µM two folds serial dilutions. (E) Ligand, 5µg/ml 
H4, analyte C4 0.125- 0.008 µM two folds serial dilutions.  
 
Further experiments were done to reconfirm the binding between 
histones and C4. Individual histones shown a comparable binding 
pattern to C4 in a different design of gel overlay assay experiment, 
when the membrane was incubated with C4 and then probed with anti 
C4 abs, the results clarified that C4 did bind to histones in a various 
pattern of affinity, (Fig. 2.10. upper). Coomassie blue stained gel 
indicates the equal loading (Figure 2.10 lower). 
 
 
 
 
 
 
 
 
 
 
Overlay 
Coomassie 
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Figure 2.10 C4 binds to individual histones. 0.25 µg of C4 besides 
two microgram of each type of histones were loaded into a 
couple of 15%SDS-PAGE. Upon the transfer of one gel, 
10µg/ml C4 was used to overlay the membrane based then 
probed with anti-C4 abs (Upper panel), while the other gel 
was stained with Coomassie Brilliant Blue (lower panel). 
 
In order to eliminate any primary abs interfering role in demonstrating 
histones-C4 binding, another gel overlay method was designed for this 
purpose, where HRP-conjugated C4 was used to overlay a membrane 
of transferred equal molar concentration of histones, in a direct 
protein-protein interaction experiment. Figure 2.11 shows that H3 and 
H4 predominantly bound to C4 and to a lesser extent H1 and H2B, 
with H2A-C4 binding undetectable using this method.  
 
Figure 2.11 C4 binds to individual histones. Two micrograms of 
H2A, H2B, H3 and H4, 4 µg of H1, and 6 µg of S100P as a 
control were subjected to SDS-PAGE. One gel was 
transferred onto polyvinylidene difluoride membrane and 
probed with HRP-conjugated C4 protein (upper panel). The 
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other gel was stained with Coomassie Brilliant Blue (lower 
panel). 
 
Interestingly, the Surface Plasmon resonance measurements have 
shown the same pattern of affinity between histones and C4, with 
regard to H3 and H4. Table 2.1 shows that H3 (KD = 0.760.12 nM) 
and H4 (KD = 0.910.07 nM) had much higher binding affinity than 
H1 (KD = 7.260.80 nM) and H2B (KD = 9.451.43 nM), with weak 
binding to H2A (KD = 12.670.59 nM). Such a link between native 
C4 and histones in this assay has suggested the possibility of its 
occurrence in vivo which may lead to various consequences in the 
complement network.  
 
Table 2.1 Kinetics of complement C4 binding to individual 
histones 
Interaction Ka (M
-1 
s
-1
)
a
 Kd (
 
s
-1
) 
b
 KD (
 
nM)
c
 
H1 4.19 ±4.72X 10
4
 7.28 ±9.52 X 10
-4
 7.26±0.80 
H2A 5.04±3.37 X 10
4
 6.39 ±5.77X 10
-4
 12.67±0.59 
H2B 8.31 ±6.76 X 10
4
 8.31±2.69 X 10
-4
 9.45±1.43 
H3 4.68±5.29X 10
5
 7.63±4.33 X 10
-4
 0.76±0.12 
H4 3.38±5.64 X 10
5
 1.03±8.9 X 10
-4
 0.91±0.07 
 
 
In most of the previous overlay experiments, the results demonstrated 
that C4 beta chain was the part that showed strongest binding to 
histones. In order to verify this outcome, the C4 beta chain was 
produced. The synthesis of C4 β chain included two domains 
production (Fragment 1-3, Fragment 4-5) to avoid technical 
production problems that associate with larger molecular weight 
proteins. Thereafter, these two domains that together compose C4 β 
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were submitted to another gel overlay experiment versus H3, which 
showed a remarkable binding affinity to the beta chain of purchased 
C4 in another experiment, (Please review fig 2.8.D). The results 
revealed and confirmed the same binding affinity between the 
complement component C4 and histones, where both C4 β chain 
constituents (Domain 1-3 and 3-5) bound to H3 in the overlay buffer 
and notably detected by anti-H3 abs, (Fig. 2.12).  
 
 
Figure 2.12 C4 Beta chain domains show binding affinity to H3. 
0.25µg of purchased C4, 0.5µg of the produced beta chain 
fragments 1-3 and 4-5 were subjected to 15%SDS-PAGE gel 
besides 6µg of S100P and 2µg of H3 as negative and positive 
controls respectively. One gel stained with Coomassie (Left 
panel) while the other one was transferred and then overlayed 
with H3 before probing with anti-H3 abs. 
 
 
 
 
 
101 
 
As my results demonstrated that the complement component C4 and 
especially the β chain have an obvious binding affinity to different 
types of histones through various tests and experimental designs, and  
since the beta chain of C4 is the part of the potent molecule C4b (178)  
that has different roles in the complement system(130, 175, 176), so it 
was a matter of concern to investigate whether such binding will 
generally affect the complement system activity or any other functions 
that are related to C4 and subsequently the domain C4b, that is 
covered in the following results chapters.   
 
2.4 Discussion 
Our group demonstrated previously that histones bind to CRP protein 
and form complexes in serum from patients with both elevated CRP 
and histones, and such binding decreased the cytoxicity of histones 
and rescued mice infused with lethal doses of histones (75). My study 
found out another protein, complement C4, could bind to histones 
when a pull down technique was utilized using histone-conjugated 
beads, to identify histone-binding proteins in critical ill patients’ sera. 
CRP as well as complement component 4 (C4) were identified by 
mass spectrometry. This has been confirmed to naturally exist by 
ELISA, histone-complement C4 complexes in patient sera. This data 
suggests circulating histones could directly interact with complement 
C4.   
Using gel overlay assay, I demonstrated that all histone (H1-H4) 
interacted with complement C4, mainly through C4 beta chain 
binding. Further mapping of the histone binding sites on C4 beta-
chain was performed by producing two recombinant proteins with 
domain 1-3, or domain 4-5 of beta-chain.  However, both proteins 
were shown to interact with histone H3 and this indicates that it is 
difficult to precisely map the binding site using current technique.  
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Since IgG has a week binding to histones, I used HRP-conjugated C4 
protein in gel overlay assay to avoid the possible cross reaction. I 
found that all histones except H2A bind to C4 protein (Fig. 2.11) 
although the single overlay was positive for H2A (Fig. 2.8 B). This 
may be due to the relatively weak interaction between H2A and C4, 
which has been confirmed by Biosensor assay. 
In conclusion, extracellular histones interact with complement C4 
beta-chain. Histone H3, H4 and H2B show high binding affinity with 
H2A having a relatively weak affinity. In vivo, histones released into 
the circulation forms complexes with complement C4. 
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Chapter 3: Effects of Histones on Complement Activation 
3.1 Introduction 
The complement system represents a unique and complex pattern 
since it is based on the composition of consecutive activated protein 
fragments, which subsequently form the convertases that cleave other 
complement proteins to compose the next enzymatic complex (119, 
165). These complexes are stable and active for a very short time as 
another form of regulatory mechanism that the complement system 
adopts to control activation (119, 166). 
The C4 concentration is about 600µg/ml in serum (177, 180). C4 full 
length protein is about 203 kDa, which is an essential part of the 
humoral immune response (173, 174). C4 is cleaved by C1s and 
MASP2 serine proteases in the classical and lectin pathway 
respectively (174), such activation results in the generation of C4b 
(195kDa) and C4a (9kDa) (175). The C4b fragment constitutes a 
subunit of the convertases C3 (C4b2a) and C5 (C4b2a.C3b), which are 
the enzymatic complexes that activate C3 and C5 of the classical and 
lectin pathways (130, 176). 
Despite sharing up to 30% sequence identity with C3 and C5, C4 
appears to be a much more sophisticated and developed protein, due to 
the formation of the three chains and the display of posttranslational 
modifications including four N- and one O-linked glycosylations and 
sulphation of three tyrosine residues (175, 179) 
C4 variants (C4A and C4B) share 99% of their sequence and vary in 
six residues only; most individuals express both isoforms (174) . C4A 
and C4B differ in their haemolytic activities and covalent affinity to 
antigens and immune complexes, in addition to variation of the 
serological reactivity (176). 
This variability of C4 could make this protein susceptible to interact 
with other molecules, where ester or amide bonds can be formed. In 
the same vein, it was found that the domain C4b binds to the 
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complement interfering protein (CIP), which is produced by the group 
B Streptococcus (GBS); this binding had suppressive effects on CP 
and MBL pathways where C4 is an important participant in their 
convertase enzymes (190).  
Although it converges with CP and MBL in terminal MAC formation, 
the alternative pathway has both unique initiation and activation 
events. Furthermore, it is distinctive in the sense of being active 
constantly at low level, thus it is primed to cope with any infection 
quickly by the slow hydrolysis of C3 (Tick over) (203, 214). In case of 
activating surface availability, C3b binds covalently to the surface and 
is able to form new C3 convertase C3bBbP in the presence of factors 
B and D (119, 214). Binding of the AP pathway C3 convertase to 
another C3b domain covalently, will create C3bBbP3b, which is the 
C5 convertase of the alternative pathway (135).  
Different methodologies have been developed to measure complement 
system activity. Mainly they are based on three major parts, which 
are: functional assays, complement analysis and the detection of 
activation products (Neoepitopes) (129). Enzyme immunoassay (EIA) 
techniques that include the three pathways are widely used in 
complement work and are commercially available nowadays (Wieslab 
Complement System Screen, Wieslab AB, Malmö, Sweden) (129, 
275, 276). This assay has many advantages over the haemolytic 
assays, since it is easy to carry out, does not require sensitized 
erythrocytes and can include the three pathways together (129). 
Other techniques to quantify complement activity via MAC detection 
or other earlier components and their activating products may include 
ELISA, cell-ELISA, flow cytometry, immunofluorescence assay 
(IFA) and Western blotting (275, 278-283). 
Zymosan has been used both in vitro and in vivo to activate CP, MBL 
and AP in several complement studies (279, 288-293). Thus it 
represents a good choice to stimulate the complement system cascade 
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and study the difference in the complement proteins levels or the total 
terminal activity versus different assigned conditions (279, 294). 
In order to block histone toxicity, heparin (17, 63, 74) and anti-histone 
abs (38, 54, 107)  have been used and found to neutralize histone 
toxicity and possess several advantageous effects both in vitro and in 
vivo. 
In this chapter, the functional effects that histones may have on 
individual and total complement activity through their binding with 
C4 which was well demonstrated in the previous chapter, will be 
studied as this may affect the related roles that are played by the CP, 
MBL and AP pathways. Thus it was interesting to understand the 
complement system response variation and the possible scenario  
during the related physiological conditions that is characterized by 
histone release and inflammatory response induction, such as sepsis 
(10) or even while complement clears apoptotic particles and necrotic 
cells (36, 131), which can be another source of extracellular histones 
and in other words DAMPs (35).   
 
  3.2 Materials and Methods 
3.2.1 Complement activity assay 
The effect of histones on complement activity in the three pathways 
was measured using a COMPL300 Total Complement Functional 
Screen kit from Wieslab (Sweden). Briefly, mixtures of the reaction 
were added to strips of wells for classical pathway (CP) estimation, 
that were precoated with IgM, strips for alternative pathway (AP) 
determination were coated with LPS, while Mannan binding lectin 
pathway (MBL) strips were coated with mannan. Normal human sera 
were diluted 1/101 (CP and MBL) and 1/18 (AP) assay in specific kit 
buffers, to ensure that only the pathway in question was activated 
(275). After one hour of incubation at 37 °C then washing the strips, 
alkaline phosphatase-conjugated antihuman C5b-9 was added before 
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incubation at room temperature for 30 min. Additional washing was 
performed, substrate was added, and the wells were incubated for 30 
min. Finally, absorbance values were read at 405 nm. In each assay, 
standard positive and negative control sera provided in the kit were 
used. The complement activity for each pathway was expressed as a 
percentage of the activity of the calibrating serum.  
 
3.2.2 C3a and C5a assays 
Serum C3a and C5a levels were measured using C3a and C5a ELISA 
kits (e-Bioscience). Samples were pre-incubated for one hour at 37°C 
in 100 µl assay buffer in the absence or presence of calf thymus 
histones (50 µg/ml) added to wells coated with IgM, mannan or LPS 
to activate CP, MBL and AP pathways respectively (190). In order to 
estimate the C3a and C5a levels upon total complement activation, 
zymosan (Comp Tech) activated serum samples (279, 289, 294) were 
pre-incubated in the same conditions without and with the 
corresponding concentration of calf thymus histones that was used to 
treat the serum samples in each pathway. Thereafter, complement 
levels of C3a and C5a were detected by the ELISA assay kit.  
 
3.2.3 Quantification of the Terminal Complement Complex (TCC, 
SC5b-9) yielded from different pathways 
The final reaction of the complement system that includes C5b-9 
formation was induced by zymosan (Comp Tech), and then measured 
using an ELISA kit from Quidel Corporation, USA. In brief, upon pre-
incubation with zymosan (279, 289, 294) in the absence or presence of 
different concentrations of calf thymus histones (0–50 µg/ml), the 
specimens were loaded into wells coated with a mouse monoclonal 
antibody that binds specifically to the C9 component of SC5b-9 and 
incubated for one hour at room temperature. Afterwards, the kit 
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instructions were applied. The control was set up as 100% and the 
effects of calf thymus histones or nucleosomes were calculated. 
 
3.2.4 Effect of nucleosomes on complement activation 
Human mono-nucleosomes purified from HeLa cells were used in this 
experiment (EpiCypher, USA). In brief, zymosan activated serum on 
its own (control), or with calf thymus histones 50µg/ml, or human 
mononucleosomes, 50µg/ml were incubated and the levels of C5b-9 
were detected by the ELISA kit from Quidel Corporation, USA. The 
samples were loaded into wells coated with a mouse monoclonal 
antibody that binds specifically to the C9 component of SC5b-9 and 
incubated for one hour at room temperature. Afterwards, the kit 
instructions were applied. The control was set up as 100% and the 
effects of calf thymus histones or nucleosomes were calculated. 
 
3.2.5 Antibody and heparin blocking assay 
An anti-histone reagent, non-anticoagulant heparin (20µg/ml, Sigma-
Aldrich, Dorset, UK) was incubated with 20μg/ml H1, H2A, H2B, H3 
or H4 proteins, or 20 μg/ml anti-histone H4 antibody incubated with 
H4, prior to complement activation using a Wieslab COMPL CP310 
kit.  The manufacturer’s procedure was followed and percentage 
changes were calculated by comparing to untreated (100%).  
3.2.6 C4 cleavage assay 
C1s (50µg/ml, Comp Tech, USA) was incubated with C4 (250µg/ml) 
in the presence or absence of histones (100µg/ml) at 37
◦
C for 30 mins, 
then 2X SDS loading buffer was added  and  boiled for 10 mins prior 
to SDS-PAGE. The gel was stained with Coomassie brilliant blue or 
subjected to Western blotting with anti-C4a antibody (Comp Tech). 
The C4a band intensities were measured using software 7.05 
GeneSnap from Syngene and fold changes were calculated. 
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3.2.7 Cell viability assay 
Viability was assessed using a WST-8 cell proliferation assay kit 
(Enzo Life Sciences), as described previously (38). Briefly, 5x10
4
 
cells were seeded into each well of a 96-well plate and grown until 
fully confluent (24 hours). Cells were treated with histones at 100 
µg/ml with and without different concentrations of C4 (10-300 µg/ml) 
for 1 hour. After treatment, the medium was changed to a fresh 100 μl 
growth media and 10 µl of WST-8 dye was added to each well, 
followed by further incubation for 2 hrs. Viability was assessed by 
measuring the absorbance at 450 nm against a reference 650 nm using 
a microplate reader (Multiskan Spectrum, Thermoelectron 
Corporation). Viability of untreated cells was set as 100% for 
comparison. 
 
3.2.8 Statistical analysis 
Intergroup differences were analyzed using ANOVA followed by 
Student–Newman–Keuls test. Two group comparisons with or without 
treatment used Student t test unless otherwise specified. P<0.05 was 
considered statistically significant. 
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3.3 Results 
3.3.1 Histones dramatically inhibit the classical and MBL 
pathways but have much less effect on the AP pathway 
To investigate the functional consequences of histones binding to C4 
that was demonstrated in chapter two, I used a complement functional 
screen kit to measure the effects of histones on the activation of the 
CP, MBL, and AP pathways. Pre-incubation of different 
concentrations of calf thymus histones (0-50µg/ml) with human serum 
significantly reduced the production of MAC by activated classical 
and MBL pathways. Significant reduction could be detected at 10 
µg/ml histones, and only trace amounts of MAC could be formed in 
the presence of 50 µg/ml histones (Fig. 3.1.A). In contrast, the same 
figure displays that histones showed much less effect on the AP, and 
50 µg/ml histones only reduced MAC formation (C5b-9) by around 
20%.  
To evaluate the overall effect of histones on complement activation in 
human serum, zymosan was used to activate complement in the 
absence or presence of histones. I found that histones at 50µg/ml 
could significantly inhibit the production of MAC induced by 
zymosan (Fig. 3.1.B).  
 
 
. 
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Figure 3.1 Histones inhibit complement activation. (A) Classical, 
MBL, and alternative complement pathways were activated by 
IgM, mannan, and LPS respectively, in the absence or presence 
of different concentrations of calf thymus histones (0–50 
µg/ml). MAC was detected by anti-human C5b-9 abs. The 
complement activity of control wells without histones was set 
up as 100%. The mean ± SD of relative activities were 
presented. (B) Shows the mean ± SD of relative activities 
activated by zymosan (activating different pathways) in the 
presence of different concentrations of calf thymus histones 
(0–50 µg/ml). *p <0.05 compared with untreated (n=3). 
 
I also assessed the role of individual histones in the classical (Figure 
3.2.A and B) and MBL (Figure 3.2.C and D) pathway activation using 
a concentration range of H1, H2A, H2B, H3 and H4 (0-50µg/ml), I 
found that 20 µg/ml individual histones started to significantly reduce 
activation of both classical and MBL pathways, with H4 and H2B 
showing the most significant effects. 
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These data highlighted that histones bound C4 could have functional 
influence on the terminal step of certain activation pathways where C4 
is a vital constituent of the convertases, taking into consideration the 
variation of individual histone impact which may due to structural 
differences among histones. 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
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Figure 3.2 Individual histones inhibit complement activation. (A 
and C) The mean ± SD of relative activities of classical and 
MBL pathways respectively, in the presence of different 
concentrations of individual histones (0–50 µg/ml). (B and D) 
The mean ± SD of relative activities of classical and MBL 
pathways respectively, in the presence of 20 µg/ml individual 
histones. Mean ± SD were calculated from at least three 
C 
D 
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independent experiments. ANOVA test, *p <0.05 compared 
with untreated. 
 
3.3.2 Anti-histone reagents can rescue complement activation 
To demonstrate the specificity of histones on complement activation 
and in particular on the CP and MBL suppression, anti-histone H4 and 
non-anticoagulant heparin, which have been shown to specifically 
inhibit histone toxicity both in vitro and in vivo (11, 38), were used. 
Heparin could reverse the inhibition of both classical and MBL 
pathways by all individual histones significantly and the activity was 
excessively close to the untreated samples in many histones types 
(Fig. 3.3.A and B).  
 
As clarified before, H4 had the strongest binding affinity to histones 
as well as being the robust CP and MBL inhibitor among the other 
types of histones, thus serum samples which are infused with 20µg/ml 
of H4 were used with and without anti-histone H4 abs. The outcomes 
demonstrated that neutralizing H4 by its corresponding abs could 
significantly rescue the H4-inhibited complement activation of both 
CP and MBL pathways (Fig. 3.4.A and B).  
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Figure 3.3 Anti-histone treatment (Heparin) rescues complement 
activation. Non-anticoagulant heparin (20µg/ml) was used to 
rescue complement activities of classical (A) and MBL (B) 
pathways inhibited by individual histones (20µg/ml). *p < 0.05 
when compared with untreated, ǂp < 0.05 when compared with 
that treated with histone alone (n=3).  
 
 
 
 
 
 
 
 
 
 
A 
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Figure 3.4 Anti-H4 abs treatment rescues complement activation. 
Anti-histone H4 Ab (12 mg/ml) was used to rescue 
complement activities of classical (A) and MBL (B) inhibited 
by H4 (20µg/ml). The mean ± SD of relative activities from at 
least three independent experiments were presented. ANOVA 
test, *p < 0.05 when compared with untreated, ǂp < 0.05 when 
compared with that treated with histone alone.  
 
 
3.3.3 Excess C4 protein only partially rescues histone-inhibited 
complement activation but significantly reduces 
cytotoxicity of histones 
Using C4 protein up to 300 µg/ml, only one third of the maximal 
complement activity of classical and MBL pathways could be 
recovered in the presence of calf thymus histones up to 20 µg/ml 
(Figure 3.5 A and B).  
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Figure 3.5 Effect of C4 protein on histones-mediated CP/MBL 
inhibition. (A and B) C4 protein affects histone-inhibited 
complement activity. Adding C4 protein (0–300 µg/ml) 
rescued 20 µg/ml histone H4-inhibited activation of CP (A) 
and MBL (B) pathway, (n=3). 
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However, the zymosan-induced complement activation could be 
recovered by 300 µg/ml C4 from 25 to 70% of total activity and hit 
the significance level in the presence of 20 µg/ml histone H4 protein 
(Fig. 3.6.A). 
 
This observation suggests that histones may also target other 
components of the complement system rather than C4 alone. In 
contrast, C4 protein could significantly reduce the cytotoxicity of 
histones to cultured endothelial cells (Figure 3.6.B). This result may 
reveal that C4 binding sites to histones could include some loci that 
are responsible for histones binding to cell membrane phospholipids, 
which is one of the histones mechanisms to cause cell toxicity and 
calcium ion influx (34, 35, 74).   
 
 
 
 
 
 
 
      
 
 
 
 
 
B 
A 
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Figure 3.6 Effect of C4 protein on histones-mediated total 
complement activity inhibition and cytotoxicty (A) 
Zymosan activated complement activity in the absence or 
presence of histone H4 20 µg/ml and C4 protein 300 µg/ml 
(histone H4/C4 molar ratio = 1:1). ANOVA test, *p <0.05 
compared to control, 
ǂ
P<0.05 compared to H4 alone, (n=3).(B) 
Human endothelial cell line, EA.hy926, was treated with 100 
µg/ml calf thymus histones in the presence of 0–300 µg C4 
proteins for 1 h. The percentage of viable cells was detected 
using WST-8 cell viability kit. Mean ± SD from three 
independent experiments are presented. ANOVA test, *p < 
0.05 when compared with histone alone, (n=3). 
 
 
 
B 
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3.3.4 Histones do not affect C4 cleavage but significantly reduce 
C3 and C5 convertase activity 
 
To clarify the molecular mechanism of histone-inhibited complement 
activation through interaction with C4, the effect of histones on the 
cleavage of C4 to C4b and C4a by C1s as well as the process of C4 
activation were investigated. I found that histones showed no effect on 
the level of production of C4a (Fig. 3.7 A and B), indicating that 
histone binding does not affect the ability of C1s to cleave C4 protein. 
 
Further investigation was carried out using gel overlay assay with 
HRP-conjugated calf thymus histones, the outcomes revealed that 
histones bind to C4b but not C4a, represented by two bands in the 
corresponding molecular weight of β and γ chains that compose C4b 
domain (Figure 3.7. C). 
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Figure 3.7 Histones show no effect on C4 cleavage and bind to 
C4b. (A) In vitro cleavage of C4 by C1s in the presence or 
absence of histones. C4 (250 µg/ml) was incubated with 
C1s (50 µg/ml, active enzyme to cleave C4 into C4a and 
C4b) ± calf thymus histones (100 µg/ml) at 37°C for 30 min 
and subjected to 8–18% gradient SDS-PAGE along with 
calf thymus histones, C4a, C4b, C4, and C1s proteins. A 
typical Coomassie Brilliant Blue–stained gel is presented. 
(B) A typical Western blot with anti-C4a Ab is presented 
(upper panel). Fold changes were calculated by setting up 
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C4a intensity without histones as 1. The relative fold 
changes of cells treated with calf thymus histones from 
three independent experiments are presented (lower panel). 
Student t test, p = 0.2. (C) Two micrograms of C4, C4b, 
C4a, and S100P (as a control) were subjected to blotting 
with HRP-conjugated calf thymus histones. A typical blot is 
presented. 
 
 
However, in the presence of histones, the production of C3a and C5a 
were significantly reduced in the classical and MBL pathways but not 
the AP and were correlated with their terminal reaction suppression 
trend (Figure 3.8.A, B and C), suggesting that histone bound C4b is 
not as efficient as C4b alone in forming active C3 and C5 convertases. 
 
 The overall C3a, C5a, and C5b-9 production induced by zymosan 
(Figure 3.8.A, B and C) were significantly reduced by histones 
because of the suppression of both classical and MBL pathways.  
 
 
These outcomes illustrate that the role of histones on complement 
activation not only affect the terminal step but also involves  different  
upstream levels in the cascade, and significantly in the CP and MBL 
pathways where C4 participates.   
 
 
 
 
 
 
 
A 
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Figure 3.8 Histones significantly reduce C3 and C5 convertase 
activities.(A–C) Complement in serum was activated by 
IgM (CP), mannan (MBL), LPS (AP), or zymosan in the 
absence or presence of calf thymus histones treated (50 
µg/ml) for 1 h at 37°C. Then, the C3a (A), C5a (B), or 
MAC levels (C) were detected by ELISA. Mean ±SD from 
at least three independent experiments are presented. 
B 
C 
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ANOVA test, *p< 0.05 when compared with that without 
histones. 
 
3.3.5 Intact nucleosomes could not inhibit complement activation 
In relation to how long histones are present in the circulation, we have 
reported that in critical illness when the buffering or clearance 
capacity is overwhelmed, histones are detectable for many days longer 
than nucleosomes (35, 37, 39, 344).  Moreover, in Chapter two (2.3.1) 
it was shown that DNA-free histones can be detected in plasma and 
serum fractions of high level circulating histones upon 
ultracentrifugation, whilst DNA-histone complexes were in fraction 6 
only.  
 
However, in order to eliminate the possibility of nucleosomes 
impacting on complement activation, I further investigated whether 
the nucleosomes themselves have any effect on complement activity 
rather than the free histones. Intriguingly, the data in Figure 3.9 shows 
that while histones could significantly suppress complement activation 
in zymosan induced serum, nucleosomes had no influence on such 
complement potency which supports the hypothesis about the effects 
of the free histones specifically on complement activation levels. 
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Figure 3.9 Effect of nucleosomes on complement activation. 
Complement activity was measured using the MicroVue SC5b-
9 Plus Enzyme Immunoassay. Zymosan activated serum on its 
own (control), or with calf thymus histones 50µg/ml (CT 
histones), or human mononucleosomes (50µg/ml) was 
incubated and the levels of C5b-9 was detected.  The control 
was set up as 100% and the effect of calf thymus histones or 
nucleosomes were calculated. Means±SD from 5 experiments 
are presented, Student t test, *P<0.01.  
 
As is known, the complement system is involved in several parts of 
the immune system including the innate and adaptive response, and 
even beyond that by crosstalk with the coagulation system (119, 220, 
297). Thus, any unusual interference with this cascade may lead to 
dysregulation of any other tasks that the complement system performs. 
In this context, I was keen to study the impact of the demonstrated 
histone-mediated inhibition of complement activation on another vital 
function that is related to complement. 
The phagocytosis process interacts with the complement system 
through several parts, whether through opsonisation by molecules like 
C4b, C3b, iC3b (304, 305), or the release of anaphylotoxins C3a and 
C5a which subsequently promote the uptake and destruction of 
pathogens by phagocytic cells (165, 172, 199).  Thus, I investigated 
this further in chapter four. 
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3.4 Discussion 
The Complement fixation process takes place via three activation 
pathways including CP, MBL and AP,  despite being different in their 
recognition strategy and effector molecules, they all share the main 
steps through the cascade which involve the C3/C5 enzymatic 
cleavage then MAC assembly (345). Complement activation generates 
MAC to lyse nucleated cells and leads to cell death and content 
release, including histones (346, 347). C4 is activated by C1s cleavage 
to produce C4a and C4b (348). The C4b is the essential component of 
both C3 and C5 convertases, a common step of both classical and 
MBL pathways. In line with C4, my data revealed that histones 
strongly bind to C4 but do not affect C4 activation as there was no 
difference in C4a production in the presence or absence of histones. 
Furthermore, the overlay outcomes demonstrated that histones bind to 
C4b in particular.  
Taking these result into consideration with major effect of histones in 
reducing the activity of C3 and C5 convertases, as indicated by 
reduction of C3a and C5a generation (products of C3 and C5 
activation), we assume that one mechanism could be the interruption 
of the convertase formation and the other could just affect the catalytic 
activity, even though the complexes are formed. Because the lifetime 
of C3 and C5 convertases in solution are very short (349), it is 
difficult to distinguish the two potential mechanisms. To be 
mentioned, the concentrations of histones used in this work were 
mainly 20-50µg/ml. For the C1s cleavage assays, we used 100µg/ml 
to demonstrate that even very high levels of histones could not affect 
C1s cleavage. From our previous publications, we have demonstrated 
that circulating histones can reach up to several hundred µg/ml in 
critically ill patients or mouse models (35, 37). However, we do not 
know if local histone levels after cell death or NET formation are 
much higher or lower. 
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In support with my data regarding C4b-mediated complement 
inhibition, Pietrocola et al clarified that C4b binds to what they called 
complement interfering protein (CIP) which is produced by the group 
B Streptococcus (GBS) (190),  this interaction between CIP and C4b 
handicapped the latter association with C2 and supposedly suppressed 
the formation of C3 convertase (C4b2C2a) which consequently 
decreased the CP and MBL complement activity, where C4 is an 
essential component in these pathways, this finding comes in parallel 
with my results with regard to histones-C4b binding effects on CP and 
MBL activity. 
 
In the other hand, there is one study suggests that histones activate 
MBL pathway (350). However, I have used their methods and 
repeated the experiments but could not find activation of complement 
by histones (Fig. 3.10). The trace amounts of signals were similar to 
that of buffer control. Besides, their work only compared the 
difference between MBL-deficient (B/B) human serum and normal 
serum without proper negative or positive controls. Therefore, their 
conclusion is not fully supported.  
 
 
Figure 3.10 Complement activation. In accordance with the 
publication of Nakamura et al, 2014, I immobilised calf 
thymus histones, recombinant human histone H1, H2A, H2B, 
H3, and H4  as well as S100P protein (for negative control) 
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on a 96-well plate using the Takara Peptide Coating Kit (Cat. 
MK100, Takara Bio, Shiga). Activation of the MBL-
dependent lectin pathway was examined using the 
Complement System Screen Wieslab kit (Euro Diagnostica, 
Malmo) with some modifications. Positive control well was 
coated with mannan, (n=3). 
 
The inhibitory effects of histones on CP and MBL pathways activity 
that I demonstrated in this study could be eliminated significantly 
upon treating the samples with  non-anticoagulant heparin, which have 
been shown to specifically inhibit histone toxicity both in vitro and in 
vivo (11, 38). Furthermore, Neutralizing H4 which has the strongest 
binding affinity with C4 by anti-H4 abs could significantly recover the 
complement activation of both CP and MBL pathways, which 
demonstrates the specificity of histones on complement activation and 
in particular on the CP and MBL suppression and expand the roles of 
both histones and their blocking molecules beyond the toxicity side to 
be engaged with complement activity inhibition/recovery. 
 
Thus, the mechanism by which histones-mediated complement 
inhibition occurs may form a physiological feedback loop to prevent 
overproduction of MAC and excessive tissue damage. This finding is 
novel, and with evidences that histone–C4 complexes exist in the 
circulation of critically ill patients, adds relevance to filling the 
unknown gap on communication between targeted cells and 
complement.  
 
 In contrast, histones have minimal effect on AP, in which C4b is not 
required. However, the overall effect is the significant reduction of C3 
and C5 activation as well as the MAC formation. This finding 
suggests that C4 is a major target of the complement system. 
Nevertheless, excess of C4 could not fully restore the complement 
activation in the presence of histones. This finding suggests that 
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histones may, have more targets on those pathways, such as C1 or C2 
(Fig 3.11). This needs further investigation. 
 
It is known that circulating C4 is ~ 0.4 mg/ml, but no histones could 
be detected in blood from healthy donors (39). In critical illness (for 
example, sepsis), histones could surge up to 100–200 µg/ml (12), but 
C4 was reported to decrease because of consumption (39). Therefore, 
the high levels of histones are sufficient to inhibit both classical and 
MBL pathways.  
 
High levels of C4 could efficiently detoxify histones in vitro, as we 
found in this study via the cell viability assay when human endothelial 
cells treated with histones, this protective effect of histones binding 
proteins phenomenon that we displayed was demonstrated in other 
publications but with other proteins rather than C4. In association with 
our groups work,  Histone-CRP complexes have been recognised in 
ICU patients’ serum with high levels of both CRP and histones (75). 
When this serum incubated with endothelial cells, CRP has shown a 
cytoprotective effect due to preventing histones from integration to 
plasma membranes and causes the consequent calcium influx and 
cytolysis, this prophylactic role due to competing for binding with 
histones to membranous phospholipids loci (75, 101).  
 
Furthermore, Bustos et al clarified the advantageous side when 
histones engaged with several serum proteins, as these histones 
binding serum proteins (HBSC) like CRP compete with anti-histones 
abs and can enhance the degradation of chromatin by complement and 
nucleases, suggesting that CRP may be important in the clearance of 
nuclear material, and illustrating that HBSC like CRP, could 
contribute to inhibit interaction of antibodies to histones and forming 
the pathological histones-immune complex, as well as preventing 
histones from engaging with glomerular basement membranes, cell 
surfaces or joints during SLE (351). 
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On the other hand, the low levels of C4 in sepsis (352, 353) may not 
be sufficient to neutralize high levels of histones. In noncritical illness, 
such as chronic inflammatory diseases with complement activation, 
the circulating histones could be very low, but the local concentration 
of histones released from lysed cells may be high and sufficient to 
suppress further complement activation and prevent excessive injury 
of host tissues. However, further laboratory experiments and clinical 
investigation are required to clarify those points. 
 
 
 
Figure 3.11 Schematic representation of the effect of histones in 
the complement pathway. 
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Chapter 4:  Effects of Histones on  Phagocytosis 
4.1 Introduction 
Phagocytosis is the process by which particles greater than 0.5µm in 
size are ingested (354). Immunologically, this mechanism is essential 
for pathogen destruction and infection elimination, as well as host 
defence stimulation (284). This form of endocytosis is a receptor-
mediated, actin- and ATP-dependent phenomenon which is initiated 
by the binding of particles or organisms to specific plasma membrane 
receptors (299, 354).   
There are four major steps that summarize this process, these include 
recognition of the target particle, signalling to trigger the 
internalization system, phagosome formation, and phagolysosome 
maturation (355). The mature phagolysosome represents the eventual 
microbicidal vesicle, where pathogens are destroyed (356). This can 
be accomplished via several anti-microbial mechanisms, such as 
acidic (357), enzymatic (358) and scavenging by dedicated molecules 
like lactoferrin (359), that remove the iron required by some bacteria 
and the NADPH oxidase that generates oxygen radicals (355).  
The internalization of damaged or senescent cells is termed as 
efferocytosis and represents the non-inflammatory form of 
phagocytosis, where ‘find-me’-signal release including nucleotides 
(ATP, UTP and the lipids lysophosphatidylcholine) recruit the 
phagocytes towards the dying cells (360). Subsequently, dedicated 
engulfment receptors identify the target ‘Eat-me’-signals such as 
phosphatidylserine and calreticulin and engulf the apoptotic cells. This 
process is followed by the release of several mainly pro-inflammatory 
cytokines to adjust the local immune response and keep the 
neighbouring cells safe (360, 361). 
Professional phagocytes include macrophages, neutrophils and 
dendritic cells which interact with the non-professional phagocytic 
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cell types such as epithelial cells, in order to mediate their activities 
(362).  
Monocyte–macrophage lineage cells exist in blood (~10% of 
leucocytes) primarily as monocytes, which are large (10 to 18 μm) 
cells with peanut-shaped, pale purple nuclei as determined by Wright 
staining (363). Mature monocytes exit the bone marrow and circulate 
in the bloodstream until they enter tissues, where they become tissue 
macrophages (363-365). 
Several assays have been developed in order to evaluate 
opsonophagocytic potency, which is implicated in vaccine production 
by testing whether the vaccine-induced antibodies drive efficient 
complement deposition and subsequent opsonophagocytic killing 
(314-316). 
Toll-like receptors (TLRs) and Nod-like receptors (NLRs) represent 
two salient members of innate immune pattern recognition receptors, 
which can elicit immediate responses against pathogenic invasion or 
tissue injury (366). DAMPs and PAMPs can both be recognized by 
TLRs and NOD-like receptors (367). TLRs are widely expressed on or 
within cells of the immune system such as macrophages and the 
epithelia and can detect a wide variety of pathogens (368). TLR2 and 
TLR4 were found to mediate phagocytosis (369), West et al 
demonstrated that the macrophage anti-microbial potency was due to 
TLR2 and TLR4 mediated stimulation (370). Yet, the innate immune 
system seems more complex than was proposed upon the discovery of 
non-TLRs, such as the NOD-like and C-type lectin receptors (371), 
e.g. macrophages isolated from NOD1-deficient mice are 
hyporesponsive to certain bacterial amino acids, mice lacking  NOD2 
were more susceptible  to Toxoplasma gondii infection (372).  
The complement system cross-talks with the phagocytotic process in 
different ways (345). For example, the generation of C3a and C5a 
upon activation results in enhanced phagocytosis, since these 
phlogistic peptides will recruit more phagocytic cells, together with 
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their anaphylatoxin role will promote pathogen degradation (165, 172, 
199). In addition, complement activation also produces other essential 
molecules like C4b and C3b, which facilitate further phagocytosis via 
their opsonisation function (172, 313). In this context, microbes are 
susceptible to phagocytosis via complement receptors on phagocytes. 
Complement receptor type 1 (CR1) is a high-affinity receptor for C3b 
and C4b fragments of complement and mediates the uptake of C3b- 
and C4b-engaged particles (368). 
Interference of the complement cascade can in turn affect complement 
fragment generation; such overlap may subsequently impact other 
activities that communicate with complement like phagocytosis, and 
represents one of the strategies that some pathogens adopt to suppress 
phagocytosis (190, 373). Based on this approach of complement-
mediated control of phagocytosis, I studied the variation of 
phagocytosis rate in phagocytes in relation to histone exposure, since I 
demonstrated that histones lead to significant reduction in C3 and C5 
cleavage, so it was a matter of concern to investigate the suppressive 
effects on phagocytosis.  
 
4.2 Materials and methods 
4.2.1 Effect of histones on phagocytosis rate and oxidative burst in 
whole blood specimens by flow cytometry. 
In order to thoroughly understand the histone-phagocytosis 
relationship, it was important to study this phenomenon while 
phagocytes are within whole blood, to mimic the in vivo physiological 
conditions and cell interactions through the haematopoietic network 
(374, 375). This novel assay measures both phagocytic uptake and the 
superoxide burst in the phagocyte populations in whole blood (376) 
and was applied according to the setting and principle displayed in 
figure 4.1 which was devised by a Liverpool School of Tropical 
Medicine research group (377). First, silica beads (Kisker Biotech, 
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Germany) were prepared from the stock by several washes and re-
suspension steps using RPMI-1640 medium. Citrated blood was 
drawn from healthy donors according to University of Liverpool 
Interventional Ethics Committee (RETH000658.089)  
The whole blood specimens (90µl) were then transferred into the 
FACS tubes that contained 10µl of the silica beads solution in 
duplicates, then 0-100µg/ml of calf thymus histones were added to 
each pair. After that, the samples were incubated with shaking at 37˚ 
C for 60min. Upon incubation and terminating the phagocytosis by 10 
min in an ice bath, 2ml of 1x Facs lysing solution was added to each 
tube and mixed gently before 20 min of incubation at 4˚ C. 
Subsequently, specimens were centrifuged for 5min at 300 g, and 
washed twice with 2ml 1xPBS before being re-suspended in 250µl 
PBS. Samples were kept on ice and phagocytosis examined by Flow 
Cytometry (BD LSR II (BD Bioscience)). 
 
Figure 4.1 Phagocytosis and oxidative burst in whole blood 
samples by flow cytometry.  Each bead is coated with IgG 
(to enhance uptake), reporter (activated green fluorescent 
emission by oxidization after entering neutrophil 
phagosomes) and calibrator (constant red fluorescent signal 
for calibration the number of beads). Therefore, the two 
fluorescent signals can be read at the same time and their 
ratios can be used to differentiate the associated beads from 
the beads that are oxidized by H2O2 in phagosomes.  
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4.2.2 Effect of histones on E coli GFP phagocytosis by U937 
macrophage like cells 
A cell line of U937 (ATCC® CRL1593.2 ™) was grown in RPMI-
1640 medium with 10% fetal bovine serum and 1% penicillin- 
streptomycin solution until an optimum growth density was achieved. 
Thereafter, cell numbers were adjusted to 1.3 ×10
5
 cells in each 
specimen using a haemocytometer (viability >95% as assessed by 
trypan blue staining). Phorbol-12-myristate-13-acetate (PMA) was 
used to trigger cell diffirentiation into adherent macrophages. 100nM 
PMA and the adjusted number of U937 cells in a total volume of 
400µl of RPMI-1640 only were used to activate cells in eight well BD 
Falcon chambered cell culture slides, these slides were incubated for 
48hrs at 37˚ C and 5% CO2 for macrophage maturation. Meanwhile, 
10µl of Green Fluorescent Protein (GFP) labelled E. coli (ATCC® 
25922GFP™) stock was incubated overnight in 5ml LB Broth, 
including 100μg/ml AMP in an orbital incubator at 37°C. The next 
day, 0.5ml of the bacterial growth was transferred into 10ml fresh LB 
broth and incubated for 30mins under the same conditions. 
Subsequently, Isopropyl β-D-1-thiogalactopyranoside (IPTG) was 
added (final concentration of 1mM) and the bacteria were incubated 
for a further 2hrs under the same conditions. Activated bacterial 
growth was then centrifuged at 2800 g for 10mins, the pellet was 
washed two times and re-suspended in 5ml PBS.  
Upon standardizing the bacterial growth density, the phagocytosis 
experiment was performed. In brief, different concentrations of calf 
thymus histones (0-100µg/ml) were loaded into the chamber slide 
wells containing the adherent PMA stimulated U937 cells, then E coli 
GFP bacteria were added (total volume of 200µl RPMI-1640). Slides 
were incubated for 1hr at 37˚ C and 5% CO2. Slides were then washed 
with PBS, then fixed and stained with 4% paraformaldehyde and 
Propidium iodide (PI) stain for 5min. Finally, slides were mounted 
and left to dry before examination with a Nikon Eclipse E600 
Fluorescence Microscope. 
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4.2.3 Western blotting and TLR blocking 
The phagocytosis experiment was carried out using U937 cells as 
mentioned in 4.2.2 with some modifications. Adherent PMA 
stimulated U937 cells were treated with 0-20 µg/ml histones. To 
investigate the role of TLR inhibition, histone (20µg/ml) treated wells 
were also incubated without or with anti-TLR2 or/and anti-TLR4 abs 
(5µg/ml final) (InvivoGen, USA). Following incubation, the slides 
were washed with PBS, but instead of being fixed as in above (4.2.2), 
60µl of clear lysis buffer was added to each well for 3min.  
Thereafter, a cell scraper was used to remove cellular extracts which 
were transferred to Eppendorf tubes for Western blotting. Samples 
were separated using 15%SDS-PAGE. Following transfer on to PVDF 
membranes, mouse monoclonal anti-GFP ab (Abcam, Cambridge, 
UK) was used to detect GFP in the cellular extracts. This experiment 
was repeated three times. Equal sample loading was determined by 
probing the same membrane with an anti-beta actin monoclonal ab 
(Sigma-Aldrich, Dorset, UK). 
 
4.2.4 Image processing software 
The Java-based image processing program (ImageJ 1.51) was used to 
count the GFP+ phagocytic cells and for Western blotting band 
quantification; data was then normalized in order to make it suitable 
for statistical analysis.  
 
4.2.5 Statistical analysis  
Intergroup differences were analyzed using ANOVA followed by 
Student–Newman–Keuls test. Two group comparisons with or without 
treatment used Student t test unless otherwise specified. P<0.05 was 
considered statistically significant. 
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4.3 Results 
 
4.3.1 Histones increase bead uptake by neutrophils in whole 
human blood 
Histones were found to interact with C4 and subsequently cause 
complement inhibition as demonstrated in Chapters 2 and 3. 
Nevertheless, it is unclear whether this inhibition in complement 
activity has other impacts on the vital early defense of innate 
immunity, such as phagocytosis, as certain complement activation 
products are opsonins for phagocytosis.   
To clarify the effects of histones on phagocytosis, we used a novel 
flow cytometry procedure to measure the phagocytic activity of 
neutrophils of specific beads within whole blood samples by gating 
the neutrophil population and counting 10,000 cells (Fig.4.2. A). Each 
bead has both reporter (activated/oxidized after entering neutrophil 
phagosomes) and calibrator (which is demonstrated neutrophil 
association but not oxidization), these two fluorescents readouts 
separate the neutrophil population into two: associated/internalized 
with or without oxidization (Figure 4.2B).  The blue dots represent the 
bead associated with neutrophils but not entered phagosomes.  In this 
way, we can clearly detect the increase in true phagocytosis and not 
the beads becoming adhered to the cells.  
Surprisingly, treating blood samples with 20 µg/ml of histones 
significantly increased the mean fluorescent intensity (MFI) (green) 
emitted by oxidization of beads inside phagosomes of neutrophils 
(Fig. 4.2.C), which indicates a significant increase in phagocytosis. A 
dose response curve was then obtained using different concentration 
of histones (0-100µg/ml), showing a plateau of uptake reached in the 
presence of 20μg/ml histones (Figure 4.2 .D).   
 
 
 
137 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
138 
 
 
 
D 
 
 
139 
 
Figure 4.2 Whole blood neutrophil phagocytosis assay. Normal 
whole blood was incubated without and with different 
concentrations of histones for 60 mins at 37°C. 
Phagocytosis was assessed by quantifying the uptake by 
neutrophils of intraphagosomal silica beads, with calibrator 
(Pacific Blue) and reporter (OxyBURST Green) 
fluorochromes. (A) Typical scatter plot demonstrating 
scatter properties of different cellular populations 
(neutrophils gated red). Uptake of intraphagosomal beads in 
the gated neutrophil population, following treatment 
without (B) and with (C) 20 µg/ml histones (Calibrator 
beads = blue; Reporter beads = green). (D) Concentration-
dependant effect of histones on phagocytosis. Means ±SD 
of fluorescent intensity of oxidised beads from 3 
independent experiments are presented. *ANOVA test 
P<0.05.  
 
 
4.3.2 Effect of histones on Escherichia coli GFP phagocytosis by 
U-937 macrophage like cells 
To demonstrate that extracellular histones could enhance phagocytosis 
of live bacteria, I used PMA-activated U937 cells as a model of 
phagocytes uptake of GFP-expressing E.coli.  Histones were found to 
enhance phagocytosis of live bacteria, by PMA-activated U937 cells 
in a dose dependent manner (0-20µg/ml) (Figure. 4.3 A- D), 
confirming the data demonstrated above.  
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Figure 4.3 Histones increase phagocytosis in U937 cells. U937 cells 
(1.3×10
5
) were activated by 100nM PMA for two days and 
adhered to eight wells chamber slide, 10:1 (Bacteria: Cells) 
E coli GFP were added to each well in a total volume of 
200µl RPMI-1640 media. The green dots represents the 
GFP within the phagocyte, the faint rounded shapes are the 
phagocytic U937 macrophage like cells. (A) Without 
histones. (B) 5µg/ml of histones. (C) 10µg/ml of histones. 
(D) 20µg/ml of histones, slides were examined by 
fluorescence microscope (20X).  
 
My data revealed that the percentage of phagocytes that engulfs 
bacteria to the total number of phagocytic cells has increased 
A B 
C D 
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significantly and dependently on increasing doses of histones, where 
20µg/ml of histones causes a large rise in this percent (Fig.4.4.A.) 
Moreover, the rate of GFP bacterial uptake was proportional to 
increase in histone dose and there was a significant difference between 
the GFP bacteria/phagocytes ratio of histone-treated U937 cells, as 
compared with untreated cells (Fig. 4.4.B).  
 
 
 
 
 
A 
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Figure 4.4 GFP bacteria/Phagocyte ratio difference. Images of 
untreated slides from three experiments as well as three of 
5, 10 and 20µg/ml histone treated chambers were processed 
using Image J analysis software. (A) The percentage of 
phagocytes that contain GFP E coli to all phagocytes count 
(B) The fine particles of engulfed GFP E coli and number of 
phagocytes were quantified, the ratio of GFP bacteria to 
phagocytes’ number then was calculated. ANOVA, p< 0.01 
when compared with untreated. 
 
 
4.3.3 Histones may interact with phagocytes through their PRRs 
Western blotting was used to further investigate the influence of 
histones on phagocytosis with E coli GFP, using anti-GFP abs. We 
investigated the possibility of histones interacting with phagocytes 
directly via PRRs, e.g. TLRs, since such sensors are widely expressed 
on phagocytes (368) and can interact with both DAMPs and PAMPs 
(367) and enhance the phagocytosis process (369, 370).  
As demonstrated in figure 4.5 (Lower panel), Western blotting  
indicated that histones trigger phagocytosis at several concentrations 
(0-20µg/ml) and there was a very strong GFP band in the 20µg/ml 
lane, which paralleled my previous findings regarding the significant 
increase in GFP particles between 20µg/ml histones and non-treated 
samples. Furthermore, use of TLR abs slightly weakened the GFP 
bands, with anti-TLR4 seeming to have the greatest effect. The upper 
panel of the same figure shows the total loaded cells indicated by beta 
actin proteins. 
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Figure 4.5 Determination of phagocytosis potency via GFP. U937 
macrophage-like cells were stimulated with 100nm PMA 
then E coli GFP bacteria were incubated with these cells, 
different concentrations of histones (5, 10, 20µg/ml) were 
used in this phagocytosis experiment along with a control 
well without histones. Anti-TLR2/4 blocking antibodies 
(5µg/ml) were also used in wells containing 20µg/ml histone 
(Lower panel). Following phagocytosis, experiments were 
terminated by the addition of clear lysis buffer, then 
subjected to Western blotting using anti-GFP abs (n=3). 
Equal loading was determined using a mouse monoclonal 
anti-beta actin abs for each membrane (Upper panel).  
 
Using Image J software to quantify the density of each band following 
phagocytosis of GFP E. coli (for both GFP and beta actin), figure 4.6 
shows that the increase of GFP protein was significant among histone 
A 
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as compared with no histone controls. In addition, anti-TLR2 and 
TLR4 abs decreased phagocytosis, demonstrated by less GFP protein. 
However, this was not statistically significant when compared to non-
TLRs abs samples with same dose of histones (Fig. 4.6). Further 
experiments need to be performed to clarify the role of TLRs on 
histone-induced phagocytosis, where by different doses of the 
antibody could be used. 
 
 
 
Figure 4.6 Estimation of phagocytosis via GFP bands 
quantification. The membrane images of three Western 
blotting experiments were processed using ImageJ software 
to evaluate the density of both GFP and beta actin bands. 
The ratios of GFP/actin (mean±S.D) for each treatment are 
presented. ANOVA test, p < 0.01 when compared with 
untreated; P<0.05 when TLRs abs samples compared with  
non-histones alone. 
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4.4 Discussion 
The complement system and phagocytosis are two interactive 
processes of innate immune response, that are closely linked (345). 
Increases in C3a and C5a generation upon activation augment 
phagocytosis through recruiting more phagocytes to the site of 
inflammation (165, 172, 199). 
Complement activation cross-talks with phagocytosis via opsonins 
fragments, such as C4b and C3b, which facilitates enhanced 
phagocytosis (172, 313) and mediate the uptake of C3b- and C4b-
engaged particles, through binding to CR1 receptors on phagocytes. 
(368). Consequently, disturbing complement activation and these 
fragments levels (C3a, C5a, C3b and C4b) are associated with altered 
phagocytosis (190, 373).  
In this study, I investigated the effect of histone-induced complement 
suppression on phagocytosis, since their presence could significantly 
reduce the production of opsonins from complement activation, such 
as C5a, C3a and C3b. Interestingly, I found that histones enhance 
phagocytosis of bacteria by both human peripheral neutrophils and 
activated U937 cells, in a dose dependent manner. Within the range of 
0-20µg/ml histones, phagocytosis increases in a concentration 
dependant manner. In the range of 20-50µg/ml, the phagocytosis 
activity reached a plateau. I also used anti-GFP antibody to quantify 
the amount of GFP that was taken up by activated U937 cells. The 
results are consistent with bacteria counting.  
As to the mechanism of histone-enhanced phagocytosis, it is not clear. 
In this study, I used anti-TLR2 and anti-TL4 antibody to block the 
known histone receptors.  I found that blocking TLR4, not TLR2, 
could reduce histone-enhanced phagocytosis although these data did 
not reach significance, suggesting histone-TLR4-myoD88 pathway 
may be one of the mechanisms. Further investigation is required. 
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Nevertheless, the roles of other receptors need to be also explored. 
Histones acting as DAMPs have been found to share several types of 
PRRs with PAMPs such as TLR4, TLR3, TLR7-9 as well as NLRs 
and RLRs (21, 378). It was found RLRs deficient mice show reduced 
phagocytic activity upon TLRs stimulation by LPS, and were also 
more susceptible to infections (379), suggesting a synergetic role 
between other receptors types in this process. In addition, 
macrophages isolated from NOD1-deficient mice are hypo-responsive 
to certain bacterial amino acid , mice lack  NOD2 were more 
susceptible  to Toxoplasma gondii infection (372). NOD1 and NOD2 
were also able to induce the auto-phagosomes formation, leading to 
uptake of invading bacteria (380). Experiments exploring the role of 
these additional receptors/pathways could be further investigated in 
near future. 
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Chapter 5: General Discussion, conclusions and future work 
5.1 Discussion 
Within cells histones are intra-nuclear proteins that pack and sort the 
DNA into functional units (Nucleosomes) and contribute in gene 
regulation (24, 381).Histones are released extracellularly via 
neutrophil extracellular traps through a process of NETosis, whereas a 
bundle of both intra-cellular and intra-nuclear components including 
histones perform a protective role against exogenous pathogens (382). 
In many critical illnesses, during cellular damage, nuclear chromatin 
is cleaved into nucleosomes, which are released extracellularly (383) 
and further degraded into individual histones (340). Histones are 
rapidly cleared by the liver (384) and are rarely detected in blood. 
Since extracellular histones were reported as a major mediator of 
death in sepsis models (34), clinical studies have found increased 
circulating histones in many critical illnesses, including severe sepsis, 
acute pancreatitis and trauma (35, 385, 386). We found that in patient 
samples, histone concentrations >50 µg/ml express direct toxic effects 
on endothelial cells (35, 75), with levels below 50µg/ml, are still able 
to trigger pro-inflammatory cytokine release (75). In human sepsis, 
median histone levels are  60 µg/ml (Quartiles 20 to 80 µg/ml), 
indicating the possible contribution of histone toxicity to the 
pathological process in at least half of septic patients (386). 
Importantly, circulating histone levels strongly correlate with disease 
severity and organ failure scores (35, 386). Circulating histones are 
also directly cardiotoxic causing elevated circulating cardiac troponin, 
but their dose-differential effect on left and right ventricular (RV) 
failure suggests the added contribution of impaired lung perfusion at 
high histone levels (387). 
In addition to histone binding to phospholipid on cell membranes to 
cause calcium influx and cell damage (35), TLR-2, -4 and -9 are also 
involved (62, 66). Extracellular histones are the most important 
DAMPs in activating immune cells, inflammasomes and releasing 
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pro-inflammatory cytokines (20, 388). Clinically, high circulating 
histone levels correlate significantly with cytokine levels and translate 
into disease severity and organ-specific injury scores, e.g. pancreatic 
necrosis (35). Histones have been shown to enhance thrombin 
generation through platelet activation and aggregation (63). High 
histone levels (>50 µg/ml) directly cause endothelial damage and low 
levels activate endothelium to release von Willebrand factor (VWF), 
recruit leucocytes/platelets and reduce thrombomodulin-dependent 
protein C anticoagulant effects (20). Whilst these are indirect 
mechanisms that link histones to thrombin generation, a more direct 
effect has been proposed, whereby histone H4 can promote 
prothrombin auto-activation into thrombin (73). However, its clinical 
relevance is unclear, since this process takes over 60 hrs to occur. 
Physiologically, prothrombin is activated very quickly by the 
prothrombinase complex, comprising the enzyme Factor Xa (FXa), 
co-factor FVa, calcium and phospholipid (PL) surfaces to localise clot 
formation (389, 390). Thus, direct molecular mechanisms of histone 
pro-thrombotic effects remain unclear.  
Besides their deleterious role (391), released to the extracellular 
spaces passively upon cell apoptosis and/or necrosis (392, 393), or 
actively through uncontrolled NETosis (27, 43, 382), histones serve as 
an alarmin to inform the body that damaging processes are occurring 
(66). Extracellular histones cause immediate increase in IL-6 release 
(within 1 hour) and lead to acute phase response. The increase in acute 
phase proteins, such as C-reactive protein (CRP), could neutralise 
histones to reduce its toxic effects (75).  Histones are also able to 
directly kill bacteria through their bactericidal properties. Therefore, 
elevated circulating histones are not solely harmful, but also trigger 
protective mechanisms within the host. My findings provide 
additional evidence for the protective mechanisms. Histone-attenuated 
complement activation and enhanced phagocytosis may be a major 
mechanism to facilitate pathogen clearance and reduce host injury.  
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Complement cascade activation has a leading role in defending the 
host against both DAMPs and PAMPs (120, 133) and the possible 
relationship between histones and the complement system has 
previously been proposed. Some studies covered the relationship 
between histones and complement system, but were mainly based on 
complement-mediated-histone release through NETosis (55, 115, 394-
396). My new approach investigating complement-histone interactions 
further aids in understand the pathology of several diseases, that are 
associated with histone release, expanding the scope of the effect of 
histone on the innate immunity and signalling (397) .  
In order to directly address the confusion as to whether histones 
themselves interact with complement or histone-DNA complexes, my 
study has clarified whether free histones circulate in blood during 
inflammatory diseases (24, 55, 66, 72, 111, 398, 399). I have clearly 
demonstrated that free histones were identified in six fractions of 
critically ill patients’ plasma following ultracentrifugation, whilst 
histones-DNA complexes were in the bottom fraction only.  
My study also highlighted that histones may interact with complement 
system in several diseases, as C4-histones complexes were increased 
significantly in critically ill patients’ plasma. C4-histones binding 
affinity was also confirmed using different assays and under different 
physiologically relevant condition (H4 > H3 > H1 >H2B > H2A). C4 
β chain displays the main binding region of C4 to histones. These data 
further extend from data presented in a previous study, where a 
shotgun proteomics study has suggested that exogenous histones 
precipitate numerous plasma proteins including complement. These 
authors were unsure as to whether these binding was a simply due to 
protein deposition or an actual binding. Data presented in my study 
clarified that histones-C4 binding occurs under physiological 
conditions, which was out of the scope of the previous publication 
(109).  
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Besides using HRP-conjugated histones in gel overlay assays against 
C4, biosensors data demonstrated the binding affinities, which further 
confirms the pattern of affinity that each histone has against C4 and 
provided detailed analysis of binding between histones and C4.  On a 
molecular basis, I also confirmed the C4 domains, produced in our lab 
were binding to histones via overlay assay. My study was the first to 
conclusively demonstrate that histones-complement binding using 
several assays, and further demonstrated that C4b is the specific 
region of the C4β chain to be the most part of C4 that interacts with 
histones.  
Complement activation generates MAC to lyse nucleated cells and 
leads to cell death and content release, including histones (346, 347). 
Interestingly, my study illustrates that histones bound to C4 affects 
complement activation in a selective manner; whereas CP and MBL 
pathways activity were significantly reduced, while this binding has 
less impact on AP pathway activation. In addition to the suppressive 
effect that histones have on CP and MBL activation, the upstream 
activity of these pathways were also decreased, as there was 
significant inhibition of both C3a/C5a generation. These data 
demonstrate inhibited convertases activity as a result of histones-C4 
binding. My data revealed that histones-C4 binding does not affect C4 
activation, since there was no difference in C4a production in the 
presence or absence of histones. Furthermore, I demonstrated that 
histone binds to C4b, an essential component of both C3 and C5 
convertases activity in classical and MBL and was able to reduce the 
activation of these pathways through inhibiting convertase activity. 
Histones had little effect on the activity of the AP pathway since C4b 
is absent in this pathway. 
Thus, it is proposed that this reduction in CP and MBL activity may 
due to histone interrupting the convertase formation through binding 
to C4. This hypothesis of C4b-mediated complement inhibition agrees 
with another study. These authors indicated that a bacterial protein 
bound to C4b and hinders its association with C2. Subsequently, the 
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formations of C3 convertase (C4b2C2a) as well as CP and MBL 
pathways activity were reduced (190). Another reason why histones 
may inhibit CP and MBL activity is the catalytic alteration of C3a/C5a 
convertases upon histone binding. However, this hypothesis is 
difficult to verify experimentally due to the short half-life of C3a/C5a 
(349).  
When both suppressive effect of nucleosomes and free histones were 
tested on complement activity, my study demonstrated that 
nucleosomes have no effect on complement activation, while free 
histones significantly reduce complement activation. These data 
clarifies that free histones but not nucleosomes affect complement 
activation during inflammatory conditions. 
Histones-mediated reduction of complement activity could 
significantly reversed when histones blocking reagents such as non-
anticoagulant heparin and anti-H4 abs (11, 38), indicating that the 
reduction in CP and MBL pathways activity is histone specific. Yet, 
other complement components rather than C4 may take part in this 
phenomenon, as C4 rescue experiments could partially recover the CP 
and MBL activity. 
Histones-mediated inhibition of complement activation may form a 
protective physiological strategy to prevent hyper tissue damage via 
excessive MAC formation (400). With evidence that histone–C4 
complexes exist in the circulation of critically ill patients, this novel 
finding exposes another aspect of cross-talk between complement and 
targeted cells, may occur in relevant medical conditions (i.e. sepsis), 
where histones levels are dramatically high and can cause CP and 
MBL activity inhibition via binding to C4, where the latter deposits 
are low due to consumption. 
 In addition, the association of C4 with histones could be 
cytoprotective since my study has indicated that C4 was able to 
neutralize histones toxicity and protect endothelial viability. However, 
it is still unclear whether histones levels following cell death or NETs 
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formation are much higher or lower in local tissues, and whether the 
low deposits of C4 in such pathological conditions are adequate to 
neutralize the toxicity of circulating histones.  Further laboratory and 
clinical work is necessary to clarify these issues. 
The complement system activity affects phagocytosis in different 
scenarios via its opsonins (C3b and C4b) and anphylatoxins (C5a, 
C3a, C4a) (165, 172, 199, 313). So, the alteration of complement 
activity by histones demonstrated in this study, may have an impact on 
the rate of phagocytosis.   
Despite the data generated in this study demonstrating the reduction in 
anaphylatoxins C3a/C5 generation as well as C4b the opsonin being 
engaged with histones, the effect of histones on phagocytosis was 
enhanced. This phenomenon of increased phagocytosis was confirmed 
and quantified using various methodologies, such as whole blood 
phagocytosis and GFP E. coli uptake (quantified microscopically and 
by Western blot).  
Since the inhibitory effect of histones on complement activity did not 
interfere with phagocytosis process, we assume that histones may 
interact directly through direct cellular binding via their receptors or 
by aggravating the inflammatory events and related mediators release 
which in turn propagate the process of phagocytosis (54, 378, 401). 
This theory would suggest a role of histones that act directly on 
phagocytosis independently of the suppression impact they caused to 
complement and its subsequent effects on phagocytosis via opsonins 
generation impairment.  
In this context, this study has found that blocking the macrophage like 
U937 cells TLRs2 and 4 receptors could reduce the phagocytosis, 
although not significantly. In support with my data, it was found that 
histones may act as DAMPs and interact with TLR2, 4 and TLR9 (54, 
61, 62, 66). Yet, other receptors role also needs to be investigated in 
this aspect, since histones as DAMPs were found to share several 
types of PRRs with PAMPs such as TLR4, TLR3, TLR7-9 and both 
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NLRs and RLRs (21, 378). Since histones may act through various 
receptors, this information may illustrate why the histones-stimulated 
phagocytosis could not be completely inhibited upon blocking TLR2/4 
and as such other types of PRRs may be involved in this mechanism. 
The limitation of this work is that the principle has not been fully 
demonstrated in vivo, including animal models and patients. This will 
be my future work to keep this research direction and try to benefit 
patients in the long run.  
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5.2 Conclusions 
 
 In critical illness, histones can exist in circulation freely not only 
within nucleosomes. 
 Histones bind to complement component C4 in different affinities. 
This binding decreased total complement activity as well as the 
classical and MBL pathways, as C4 is the main protein in the C3 
and C5 convertases of these pathways. While the AP activation is 
slightly influenced by C4-histones interaction, due to the different 
composition of C3, C5 convertases.  
 The mechanism by which histones-mediated complement 
inhibition occurs may form a physiological feedback loop to 
prevent overproduction of MAC and excessive tissue damage. 
 Other complement components may interact with histones, since 
rescue C4 experiments could only partially restore the activity. 
 Anti-histone antibodies may have promising therapeutic purposes 
in both histones toxicity neutralization and complement function 
recovery in certain cases where such immune defense is required. 
 Histones may enhance phagocytosis in a complement independent 
manner that may act through TLRs and other PRRs.  
 Comprehensive understanding of the crosstalk inside this vital 
triangle of innate immunity (Complement-phagocytosis-TLRs) and 
histones impacts on this interaction may help in developing 
effective therapeutic strategies in related medical conditions such 
as sepsis. Thus further studies are requisite to achieve this target. 
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5.3 Future work 
 Investigating other possible interactions of complement proteins 
like C2 with histones. 
  Applying complement-histone approach locally, by studying the 
effect of this binding in body fluids of damaged tissue.  
 Studying the effect of histones on phagocytosis in association with 
other signaling molecules like NOD-like receptors. In parallel with 
complement activity evaluation under the same conditions. 
 Using animal models to demonstrate the principles established in 
vitro. 
 Clinical studies to explore how to benefit patients via my 
discovery. 
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